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Abstract 
Parkinson's disease is caused due to the progressive loss of dopaminergic neurons 
in the brain. Less than 10% of cases have a strict familial etiology while more than 90% 
are sporadic. The mechanisms underlying neuronal cell death in Parkinson's disease have 
not been fully elucidated. Furthermore, there is currently no therapy available to prevent 
the progressive loss of neurons in Parkinson's disease. The objective of my research was 
to establish a sporadic model of Parkinson's disease and evaluate the neuroprotective 
effects of water soluble Coenzyme Qio. In this study, a model of paraquat-induced 
neurodegeneration in rats was used to evaluate the efficacy of water soluble Coenzyme 
Qio as a neuroprotectant. The results revealed a loss of dopaminergic neurons in the 
substantia nigra pars compacta region of the brain in paraquat-injected rats. Increased 
levels of oxidative stress and activated astrocytes were also observed in rats treated with 
paraquat. Furthermore, the behavioural tests uncovered deficiencies in fine motor skills in 
these rats. In parallel, rats that received water soluble Coenzyme Qio in their drinking 
water showed significant neuroprotection against paraquat toxicity including behavioral 
improvements, reduced loss of dopaminergic neurons and lowered levels of oxidative 
stress. Interestingly, this neuroprotection was accompanied by an increased numbers of 
activated astroglia in the midbrain. The ability of this formulation of Coenzyme Qio as a 
therapeutic agent was also studied; preliminary results indicate that it offers 
neuroprotection. Pilot studies revealed that paraquat-induced dopaminergic loss increases 
with age. Altogether, this study confirmed the neurotoxicity of paraquat, especially 
towards dopaminergic neurons, and provided a rat model of Parkinson's disease suitable 
for mechanistic and neuroprotective studies. This is the first preclinical evaluation of 
v 
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Parkinson's disease (PD) is characterized by the loss of dopamine producing 
neurons present in the substantia nigra pars compacta region in the brain. Motor function 
is affected in this disease. This chapter introduces the anatomy of the brain region 
affected by PD, as well as the different dopaminergic pathways and the pathway 
associated with PD. The causes of PD, the various models used for studying PD and the 
mechanisms of cell death in PD are also addressed in this chapter. Lastly, the different 
mechanisms underlying neuronal cell death in PD, and the neuroprotective strategies that 
are used to treat people with PD are discussed. 
1.1 The Basal Ganglia Circuitry 
The basal ganglia (BG) consist of a large and functionally diverse set of nuclei, 
which lie deep within the cerebral hemispheres. The subset of nuclei involved in motor 
control include the caudate nucleus, putamen (caudate and putamen together form the 
striatum), the globus pallidus: pars externa (GPe), and pars interna (GPi), subthalamic 
nucleus (STN) and the substantia nigra (SN) (Bjarkam and Sorensen 2004) (Figure 1.1). 
According to the classical model, the basal ganglia form a complex network that 
integrates areas of the cerebral cortex, basal ganglia nucleus and the thalamus 
(Alexander and Strick 1986). In this complex circuit, the neurons from the cortical areas 
project into the striatum, especially the putamen. The striatum also receives projections 
from the amygdala and hippocampus (Groenewegen 2003). These inputs into the 
striatum are all excitatory. The transfer of cortical and thalamic information in the 
1 
striatum is modulated by dopaminergic inputs from the substantia nigra pars compacta 
(SNc). The globus pallidus and the substantia nigra pars reticulata are the main sources 
of output from the basal ganglia. 
The signals for intentional movements are initiated in the cerebral motor cortex 
and eventually reach the brain stem. From here they reach the muscles, but before they 
do so, centers such as the cerebellum and the basal ganglia pose their influence on these 
signals. Both these centers exert their influence on the final motor signals via the 
thalamus (Groenewegen 2003). 
Figure 1.1 A coronal section showing the components of the basal ganglia in 
the human brain. The figure shows the arrangement of the caudate nucleus, putamen, 
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The efferent projections from the striatum to the basal ganglia are segregated into 
two pathways (for a representation of the basal ganglia circuitry, refer to Figure 1.2). In 
the direct pathway, the neurons from the putamen directly project into the globus 
pallidus pars interna and the substantia nigra pars reticulata (SNr). Neurons in this 
pathway bear the D1 dopamine receptor subtype and provide a direct inhibitory effect on 
GPi/SNr (Figure 1.2A). In the indirect pathway, the neurons from the putamen connect 
with the GPi/SNr via the globus pallidus pars externa (GPe) and the subthalamic 
nucleus. The neurons in this pathway have D2 dopamine receptor subtype, and cause the 
excitation of GPi/SNr (Bjarkam and Sorensen 2004) (Figure 1.2B). Under normal 
circumstances, the dopaminergic neurons present in the substantia nigra pars compacta 
will supply dopamine to the striatum via the nigrostriatal pathway, stimulating neurons 
expressing D1 receptors and inhibiting neurons expressing D2 receptors (Bjarkam and 
Sorensen 2004). Thus the output from the basal ganglia is influenced by the opposing 
effects of the direct and indirect pathways. An abnormal decrease or increase in the 
activity of the basal ganglia output, is associated with Parkinsonism and dyskinesias 

































Figure 1.2 The basal ganglia circuitry. The efferent projections from the striatum to the 
basal ganglia are segregated into two pathways namely the direct pathway (A) and 
indirect pathway (B). 
4 
1.2 Dopamine in the Nigrostriatal Tract 
Dopamine is a member of the class of catecholamines, along with epinephrine and 
norepinephrine. The first, and rate-limiting, step in catecholamine synthesis is the 
enzymatic conversion of tyrosine to dihydroxyphenylalanine (DOPA) by tyrosine 
hydroxylase (Figure 1.3). Dopamine is synthesized in the cytoplasm of the presynaptic 
terminals and stored in vesicles by a vesicular monoamine transporter (VMAT). Upon 
release in the synaptic cleft, its action is terminated by re-uptake into the terminal or 
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Figure 1.3 Catecholamine synthesis. Dopamine functions as both a neurotransmitter 
and a precursor for other catecholamines. Tyrosine hydroxylase is the rate-limiting 
enzyme. 
6 
Two enzymes are involved in the catabolism of dopamine: mitochondrial 
monoamine oxidase (MAO) and cytoplasmic catechol-O-methyltransferase (COMT). The 
final product of the breakdown of dopamine yields homovanilic acid (Figure 1.4) 
(Dziedzicka-Wasylewska 2004). 






acetic acid (DOPAC) 
HaC 
3-Methoxytryamine (3-MT) 
C atechol-0 -m ethyl-
transf erase (COMT) 
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Aldehyde Dehydrogenase 
Homovanilic acid (HVA) 
Figure 1.4 Dopamine catabolism. Dopamine is broken down into homovanilic acid by 
two different enzymes. 
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1.3 Dopaminergic Pathways 
Many of the dopaminergic neurons in the central nervous system are positioned in 
the midbrain, and are divided into four functional and anatomical groups: mesolimbic, 
mesocortical, nigrostriatal and tuberoinfundibular dopaminergic neurons. These circuits 
are involved in the regulation of a wide range of processes, from circadian rhythms to 
depression and reward-based behavior (Dziedzicka-Wasylewska 2004). 
The mesolimbic pathway arises in the ventral tegmental area (midbrain) and 
innervates the nucleus accumbens and olfactory tubercle in the ventral striatum and parts 
of the limbic system including the septum, amygdyla and pyriform cortex. This pathway 
is thought to be essential for motivated behaviours such as activity related to reward and 
the positive reinforcement from frequently abused drugs, for instance alcohol, cocaine, 
amphetamines and opiates. The mesocortical dopaminergic pathway also originates in the 
ventral tegmental area and innervates the frontal, cingulate and entorhinal cortices. These 
areas are involved in emotional, motivational and cognitive functions, such as certain 
aspects of learning and memory. It is broadly acknowledged that the mesocorticolimbic 
dopamine system plays a pivotal role in mediating acute rewarding effect of drugs of 
abuse. Finally, the nigrostriatal pathway projects from the substantia nigra pars compacta 
and innervates the dorsal striatum and is involved in motor control (Dziedzicka-
Wasylewska 2004). Imbalance in this pathway is associated with Parkinson's disease and 
is associated with bradykinesia and hypokinesia (Groenewegen 2003). 
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1.4 Parkinson's disease 
Parkinson's disease (PD) is the second most prevalent neurodegenerative 
disorder, and was first described by James Parkinson in 1817 (Schober 2004). The 
prevalence of PD is 1-2 per 1000 (Bartels and Leenders 2009). The cardinal feature of 
this disease is dopamine deficiency arising due to a progressive degeneration of 
dopaminergic (DA) neurons in the nigrostriatal pathway. The dopamine neurons play an 
important role in coordinating normal motor function. Post mortem studies have 
revealed a decrease in the levels of dopamine and its metabolites in the different areas 
including the globus pallidus, putamen, caudate, nucleus accumbens and the substantia 
nigra of PD patients. Clinical symptoms such as resting tremors, bradykinesia, rigidity 
and postural instability arise when about 60-70% of the DA neurons are lost, leading to a 
decline in dopamine levels in the nigrostriatal pathway (Lang and Lozanol998). 
Besides the dopaminergic defects, PD is assumed to be a multi-centric disease. It 
is also believed that there is an association between the nigrost riatal degeneration and 
degenerative process elsewhere in the central and peripheral nervous system. Three 
possible scenarios are hypothesized: damage to the SNc and other regions occur 
simultaneously, the disease primarily begins in the SNc and this influences the 
involvement of other areas; or, the involvement of the SNc occurs later in the disease 
(Lang and Lozano 1998). Lewy bodies are found in the degenerating DA neurons of PD 




The prevalence of Parkinson's disease (PD) in individuals over 50 years of age is 
1 to 2% (Battels and Leenders, 2009 2009). Most cases (95%) are of unknown etiology 
(Corti et al. 2005). Epidemiological studies have shown PD concordance rates to be 
similar between monozygotic and dizygotic twins (50 years of age), indicating that 
heredity is not a major etiologic component. Tanner screened 19,000 monozygotic and 
dizyogotic twins for PD and found that there were very similar concordance rates 
between the two types of twins (1989a). This result led Tanner to conclude that "genetic 
factors do not play a major role in causing PD." Studies designed to understand the role 
of environmental toxins explored geographic differences in PD prevalence. Evidence 
pointed to a higher incidence of PD in industrialized nations. For example, PD 
occurrence was correlated to exposure to industrial chemicals, quarries and printing 
plants in China (Tanner et al. 1989b). Similarly, extensive pesticide use was associated 
with increased incidence of PD in California. In fact, the incidence rate of PD between 
1984 and 1994 was reportedly higher in California, a state which uses almost a quarter 
of all pesticides in the US (Ritz and Yu 2000). 
1.6 Models to Study Sporadic/Idiopathic Parkinson's disease 
Much of the information regarding the etiology and pathogenesis of PD is obtained 
from clinical studies, post-mortem studies, and epidemiological studies. Accessibility to 
a human brain is limited because of ethical approval, availability of postmortem brain 
tissue, and difficulty in drawing definitive conclusions due to individual variability and 
differences in tissue quality (Emborg 2004). Animal models are therefore an important 
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tool to study the pathogenesis and strategies for therapeutic intervention of PD. 
Parkinson's disease does not spontaneously develop in animals; therefore neurotoxic 
agents have to be used to induce the characteristic functional changes associated with 
PD. Ideally, animal models of PD should show all the clinical characteristics and 
pathological features observed in people. Some of the prominent toxin-induced PD 
models are discussed below. 
1.6.1 MPTP Model 
A major breakthrough in PD research came in the 1980's when a model to study 
sporadic/idiopathic PD was accidentally discovered. In 1983 Langston and his 
colleagues reported parkinsonian syndrome in young addicts that was clinically 
indistinguishable from PD after injecting themselves with a synthetic narcotic. The 
toxic compound was identified as l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine 
(MPTP) by chemical analysis. Post mortem analysis revealed selective loss of neurons 
in the substantia nigra and Lewy-body-like inclusions. Intravenous use of MPTP caused 
all the key signs of Parkinsonism. The striking similarities between sporadic PD and 
MPTP-induced Parkinsonism suggested that compounds similar to MPTP in structure 
or biological activity might be the primary cause of sporadic PD (Smeyne and Jackson-
Lewis 2005). 
MPTP by itself is not toxic. It is a lipophilic compound that easily crosses the 
blood brain barrier upon administration. MPTP is converted to its toxic metabolite 1-
methyl-4-phenyl pyridinium ion (MPP*) by monoamine oxidase B especially in non-
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dopaminergic cells such as astrocytes (Di Monte 2003, Przedborski and Vila 2003, 










Figure 1.5 Metabolism of MPTP in glial cells. In the presence of monoamine oxidase, 
l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine (MPTP) is converted to l-methyl-4-phenyl 
pyridinium ion (MPP+) which is the toxic to the dopaminergic neurons. 
MPP+ is a substrate for the vesicular monoamine transporter (VMAT), which 
translocates MPP+ into synaptosomal vesicles, and also for the dopamine transporter 
(DAT) present on dopaminergic neurons and for norepinephrine-serotonin transporters. 
(Javitch et al. 1985, Daniels and Reinhard 1988, Przedborski and Vila 2003). Upon 
entering a dopaminergic neuron, MPP+ can be concentrated by an active process within 
the mitochondria where it impairs electron flow through the electron transport chain by 
inhibiting complex-I. 
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MPTP induces the symptoms of PD in rodents, cats, non-human primates and 
mini-pigs (Terzioglu and Gaiter 2008). Neuropathological studies in humans and 
monkeys indicate that MPTP induces damage to the dopaminergic neurons in the 
nigrostriatal pathway identical to that seen in PD (Bove et al. 2005). MPTP is usually 
administered systemically (subcutaneous, intraperitonial, intravenous or intramuscular). 
In non-human primates, unilateral intracarotid infusion of MPTP is often used to 
administer the drug. Susceptibility to this compound varies in different species. A 
multitude of regimens and doses of MPTP (acute, chronic) are used to study PD (Betarbet 
et al. 2002). Acute MPTP administration induces specific degeneration of dopaminergic 
neurons in the substantia nigra (between 50 and 93% loss) while chronic administration 
of MPTP induces about 50-60% loss of dopaminergic neurons (Betarbet et al. 2002). 
Although numerous studies with MPTP have been conducted in monkeys, molecular 
mechanisms underlying MPTP-induced toxicity are largely studied in rodents such as 
mice (systemic injections) and, albeit to a lesser extent, in rats (intracerebral injections) 
(Bove et al. 2005). 
Neurochemical changes that accompany MPTP exposure include decreased levels 
of dopamine and its metabolites in the striatum as well as and increased oxidative damage 
(Betarbet et al. 2002). Systemic MPTP administration in mice induces PD-like 
symptoms, including bradykinesia, rigidity and posture anomalies. These symptoms 
parallel the low dopamine neuron counts that also result due to MPTP exposure (Sedelis 
et al. 2001). Studies have also investigated the role of MPTP on motor behaviour 
including locomotion, circling, rearing and/or stereotyped behaviour (Sedelis et al. 2001). 
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1.6.2 Pesticide/ Herbicide Induced PD Models 
Several epidemiological studies have revealed a link between environmental 
factors such as farming and exposure to chemicals used in agriculture, and increased 
incidence of PD (Tanner et al. 1989b). A number of environmental stimuli are 
associated with the disease including herbicides, pesticides, cyanide, carbon monoxide 
and heavy metals (Uversky 2004). Over the years there has been an increased focus on 
the association between pesticide exposure and incidence of PD. Studies have shown a 
strong correlation between long term pesticide exposure and increased risk of PD 
(Brown et al. 2006). It has been hypothesized that many chemicals used in agriculture 
are capable of selectively targeting dopaminergic neurons, thereby accelerating the 
development of PD. In order to better understand the role of environmental toxins in 
PD many toxin-based models have been developed. 
1.6.2.1 Paraquat Model of PD 
Paraquat (PQ), or 1, l'-Dimethyl-4, 4'-bipyridinium, is a quaternary nitrogen 
herbicide commonly used to kill broad leaf weeds. Although banned in the United States 
and countries of the European Union, it is still used in many developing countries. For 
many years, experimental studies using PQ focused on its deleterious effects on the lungs, 
liver and kidneys because acute exposure can induce toxicity and even death (Bove et al. 
2005). Epidemiological studies in Taiwan, where PQ is commonly sprayed on rice fields, 
showed that people exposed to PQ for at least 20 years had almost a 600% higher chance 
of developing PD (Liou et al. 1997). These studies raised the possibility that PQ could be 
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an environmental Parkinsonian toxin. Also interesting to note is that the structure of PQ 
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Figure 1.6 The chemical structures of PQ, MPP+ and MB. 
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Paraquat is a hydrophilic, charged molecule and therefore does not diffuse across 
cell membranes, including the blood brain barrier (Dinis-Oliveira et al. 2006). Studies 
have shown that PQ enters the central nervous system through neutral amino acid 
transporters located in the blood brain barrier (McCormack and DiMonte 2003). Co­
administration studies using PQ and competitive inhibitors of neutral amino acid 
transporters (e.g., L-valine, L-phenylalanine, L-dopa), revealed a prevention in PQ 
induced neurotoxicity (McCormack and DiMonte 2003). 
The cellular toxicity of PQ is mainly due to its' ability to participate in reactions 
that produce reactive oxygen species (ROS). In the cell, PQ is reduced to form a 
monocation free radical (PQ*4) by either NADPH-cytochrome P450 reductase (Clejan 
1989), cytochrome c reductase (Fernandez et al. 1995), or complex I of the mitochondrial 
electron transport chain (Fukushima et al. 1993) (Figure 6). The monocation free radical 
form of PQ then reacts with oxygen to form a super-oxide radical (O2 "). Once the super­
oxide radical is formed, it can react through well known mechanisms to create other 
reactive oxygen species, all of which are harmful to cells (Dinis-Oliveira et al. 2006). 
Moreover, it is believed that the redox cycling process of PQ depletes intracellular stores 
of NAD(P)H due to its increased oxidation, thus contributing to the toxicity of this 
herbicide (Dinis-Oliveira et al. 2006). PQ*+ can also reduce iron (III) and iron (III) 
chelates, in turn catalyzing the formation of hydroxyl radicals via the Fenton reaction 
(Hastings 1995). PQ, like MPTP has been used to induce PD in rodents (mice and rats) as 
well as in monkeys (Bove et al. 2005). Systemic exposure to PQ in mice and rats results 
in loss of dopaminergic neurons especially in the SN region, and reduction in the density 
of striatal TH-fibres (von Bohlen und Halbach et al. 2004). Intraperitonial injections of 
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10 mg/kg PQ in mice have shown to create a selective loss of dopaminergic neurons in 
the SN region (McCormack et al. 2002). 
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Figure 1.7 Reduction-oxidation cycling of PQ. PQ is reduced to form a monocation 
free radical (PQ*+) by either NADPH-cytochrome P450 reductase cytochrome c 
reductase, cytochrome c reductase, or complex I of the mitochondrial electron transport 
chain. The monocation free radical form of PQ then reacts with oxygen to form a super­
oxide radical (02* ). 
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Early studies of PQ-induced PD in animal models were unsuccessful in observing 
any changes in the nigrostriatal DA pathway following systemic exposure to PQ (Bove et 
al. 2005). However, with the introduction of stereological cell counting following sub­
lethal dosing of PQ over a 3-week period shows a decrease in TH-positive cells in the 
SNc. In addition, DA neurons in the SN and striatum appear particularly sensitive to PQ, 
as other subpopulations of neurons were unaffected (Bove et al. 2005). Reduced motor 
activity and dose dependent losses of striatal DA nerve fibres were also reported in mice 
receiving multiple PQ injections (Brooks et al. 1999). While no significant depletion of 
striatal DA has been observed following PQ injections in vivo, evidence for enhanced DA 
turnover is suggested by increases in TH activity and altered DA metabolite levels 
(McCormack and DiMonte 2003). 
Additional evidence to support the status of PQ as a parkinsonian toxin comes 
from data indicating upregulation and aggregation of a-synuclein within SNc neurons in 
treated mice (Manning-Bog et al. 2002). Significant amplification in 4-hydroxynonenol 
positive neurons and nitrotyrosine immunoreactivity in nigral cells of PQ-treated mice 
provide further evidence for oxidative injury in the SNc (McCormack et al. 2005). 
Although PQ exerts its toxicity via oxidative stress, it also triggers the activation of c-
Jun-N-terminal kinase (JNK) and caspase-3 in both in vitro and in vivo conditions, 
suggesting that JNK pathways could mediate paraquat-induced neurodegeneration (Peng 
et al. 2004). 
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1.6.2.2 Paraquat-Maneb Model: The Multi-hit Hypothesis 
Most studies identifying environmental toxins that target DA neurons have 
focused on the use of a single chemical to induce PD. Nonetheless, humans may be 
exposed to multiple toxins in their environment. The multi-hit hypothesis proposes that 
the brain is able to resist the effects of an individual chemical that targets DA neurons; 
however, the defence machinery may be compromised when several toxins target 
different sites in the DA system, ultimately leading to neuronal damage and cell death 
(Brown et al. 2006). Of the different models using combinations of toxins to study PD, 
the PQ-Maneb combination has been shown to act synergistically to induce PD-like 
pathology. Maneb is a commonly used fungicide (for structure, refer to Figure 1.6). 
Studies using a combination of Maneb (MB) (30 mg/kg) and PQ (10 mg/kg) have shown 
greater neuronal damage than what is induced by either chemical alone (Cory-Slechta et 
al. 2005). The PQ-MB model has been used to study the effect of exposure to multiple 
environmental neurotoxins on the risk for PD development (Thiruchelvam et al. 2000a). 
1.7 Molecular Mechanisms Contributing to Toxin-induced Neurodegeneration in 
PD 
The mechanisms involved in the progressive loss of dopaminergic neurons in PD 
are of foremost interest in the field of PD. Though the exact mechanism of neurotoxicity 
is not yet fully known, oxidative stress, mitochondrial dysfunction, excitotoxicity and 
neuroinflammation are all believed to play an important role in the death of SN neurons. 
These mechanisms are discussed below. 
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1.7.1 Oxidative Stress 
Mounting evidence supports the theory that oxidative stress may contribute to PD 
pathogenesis (von Bohlen und Halbach et al. 2004). The brain depends mainly on 
energy produced from the mitochondria, and approximately 95% of the molecular 
oxygen that is inhaled is metabolized by the mitochondrial electron transport chain. 
This causes the mitochondria to be exposed to high levels of reactive oxygen species 
(ROS) and oxidative stress that can damage distinct neuronal populations (Tritschler et 
al. 1994). 
High levels of ROS cause oxidative stress, which refers to the undue oxidation of 
biomolecules leading to cellular damage. ROS include a number of reactive molecules 
derived from oxygen (Valko et al. 2007). Stepwise reduction of molecular oxygen 
leading to the formation of ROS like superoxide and hydrogen peroxide is shown in 
figure 1.8. 
02̂ * 0:"-k. H^ChivOH + OH -k. 2H;0 
2H+ 2H* 
Figure 1.8 Stepwise reduction of molecular oxygen. 
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Production of the superoxide anion radical occurs mostly in the mitochondria and 
it is converted to hydrogen peroxide (H2O2) by superoxide dismutase (SOD). H2O2 is not 
a free radical but can penetrate cell membranes making it very toxic to the cell. In the 
presence of iron, the Fenton reaction converts H2O2 to the OH* radical. This radical is 
likely capable of causing more damage than any other ROS (Betteridge 2000). These 
oxygen radicals can induce mitochondrial dysfunction, accelerating the production of 
more reactive oxygen species, thereby escalating and perpetuating the vicious cycle (von 
Bohlen und Halbach et ah 2004). Additionally, superoxide radical can react with nitric 
oxide (NO) to form peroxynitrite anion (ONOO ), which is highly reactive and can be 
neurotoxic (von Bohlen und Halbach et ah 2004). 
ROS can react with proteins, DNA and lipids. In vitro studies revealed that ROS 
can directly react with several amino acid residues leading to less active enzymes and 
malfunctioning proteins. ROS can cause modifications in DNA leading to mutagenesis. 
ROS have also been shown to target mitochondrial DNA. In many cases apoptosis, a 
form of programmed cell death is mediated by ROS (Valko et ah 2007). 
1.7.1.1 Oxidative Stress in PD 
The contribution of oxidative stress in PD nigral cell death has been demonstrated 
by post-mortem studies in PD patients as well as by toxin-induced PD models (Jenner 
2003; Dickson 2007). Even under normal conditions, the substantia nigra (SN) region is 
subjected to oxidative stress due to production of ROS during dopamine metabolism, 
high levels of essential cofactors iron and copper for catecholamine metabolism, and/or 
high levels of oxidized GSH (Spina and Cohen 1988, Dickson 2007). Dopamine 
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autooxidation leads to production of H2O2, which is converted to the extremely toxic 
hydroxyl radical (Youdim et al. 1989) (Figure 1.9). 
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Figure 1.9. Dopamine autooxidation. Autooxidation of dopamine leads to the 
production of superoxide anion radicals, which can then be converted to hydroxyl radical. 
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Post mortem studies of PD patients have shown higher than normal iron levels in 
the SN region (Andersen 2004). 
Although ROS levels cannot be measured directly, the assessment of their 
reaction products and the concomitant damage in post mortem tissues serve as indirect 
evidence of increased or decreased levels. The evidence for increased oxidative damage 
include increased levels of lipid peroxidation, DNA damage and protein oxidation 
observed in the SN region in PD patients (Sanchez-Ramos 1994, Yoritaka et al. 1996, 
Alam et al. 1997a, Alam et al. 1997b, Floor 1998, Zhang et al. 1999). In the brain, GSH 
is known to play a vital role in detoxification of ROS (Dringen 2000). A decrease in the 
levels of reduced GSH by about 50% in PD substantia nigra is also evidence of increased 
oxidative stress (Perry 1982, Perry 1986, Riederer 1989, Beal 2003a). Lower glutathione 
content appears to be the earliest marker for oxidative stress during the progression of PD 
(Nakamura 1997). 
Interestingly, nitric oxide (NO) can cause nitrosative damage by displacing iron 
from ferritin, leading to degeneration of the cells in PD (Beckman et al. 1990, Reif and 
Simmons 1990, Shergill et al. 1996). NO inhibits glutathione reductase and also causes 
DNA single-strand breaks and increases DNA oxidation (Sanchez-Ramos 1994, Alam et 
al. 1997a, Barker et al. 1996). It is known that parkin has ubiquitin-3 ligase like activity 
and S-nitrosylation of parkin may impair its ability to ubiquitinate proteins (Schapira 
2008). NO also inhibits the mitochondrial respiratory chain and enhances damage caused 
to the mitochondria by toxins such as MPP+ (von Bohlen und Halbach et al. 2004). 
It is yet to be determined which of the two species, ROS or reactive nitrogen 
species (RNS), is the main culprit in the development of PD. Furthermore, oxidative 
stress is linked to other cellular processes such as cell death, inflammation, excitotoxicity 
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and mitochondrial dysfunction, so it is not easy to establish whether oxidative stress is 
the primary initiating agent or a product of these events (Jenner 2003, Andersen 2004). 
1.7.2 Mitochondrial Dysfunction in PD 
Mitochondria are the primary site for energy production, which is regulated by 
five respiratory complexes. There is mounting evidence suggesting the involvement of 
mitochondrial dysfunction and impairment of complex I in the onset of PD (Koller and 
Cersosimo2004). Many environmental toxins including rotenone, MPP+ and PQ are 
known to inhibit complex I of the mitochondrial electron transport chain (Fukae et al. 
2007). Studies involving toxin-induced PD in animal models have revealed a loss in the 
activity of complex I by MTPT and rotenone. Post mortem studies of PD patients 
indicate a 30-40% loss of activity of complex I in the SN region (Bove et al. 2005). 
Reactive oxygen species (ROS) such as the superoxide anion radical can 
reversibly and irreversibly inhibit complexes I and IV, and although the mechanism of 
action of reactive nitrogen species (RNS) remains vague it is hypothesized that NO may 
be involved in the S-nitrosylation of thiol groups in these complexes (Barker et al. 1996) 
Mitochondria are responsible for generating ATP through oxidative 
phosphorylation and mitochondrial dysfunction caused by oxidative stress can lead to a 
decrease in ATP production, which may contribute to cell degeneration in PD (Andersen 
2004). Indeed, in vitro studies in our lab indicate that oxidative stress causes a decline in 
mitochondrial ATP production in neuroblastoma cells (McCarthy et al. 2004). Reduced 
ATP levels causes inhibition of PA700, an activator of the 26S proteasome, resulting in 
decreased ubiquitination (Jenner 2003). Additionally, mitochondrial dysfunction leads to 
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the failure of ATP-dependent magnesium inhibition of N-methyl-d-aspartate (NMDA) 
receptors thereby escalating vulnerability to excitotoxicity (Koller and Cersosimo2004). 
1.7.3 Excitotoxicity in PD 
There is no direct evidence to implicate excitotoxicity in PD; however, it has been 
suggested that glutamate may have a toxic effect on DA neurons in the SN region since 
this region receives glutaminergic projections from the subthalamic nucleus (STN) 
(Groenewegen 2003, Henchcliffe and Beal 2007). Under physiological conditions in 
striatum there exists a neurotransmitter balance between the activation of striatal 
neurons through N-methyl-D-aspartate (NMDA) receptors and inhibition by the D2 
dopamine receptors. In PD patients, depleted nigrostriatal dopamine results in 
disinhibition of the neurons in the striatum and therefore leads to glutamatergic 
overactivity (Lang and 0beso2004a). Due to increased glutamate binding onto the 
NMDA receptors, there are changes in cell permeability to calcium. The pathological 
activation of NMDA receptors causes massive Ca2+ entry into neurons, where Ca2+ 
accumulates in the mitochondria. Matrix Ca2+ accumulation is proposed to produce 
high levels of superoxide and other reactive oxygen species that damage the 
mitochondria and thus the cell, ultimately causing neuronal cell death. The two 
mechanisms involved in calcium dependent NMDA neurotoxicity are: excessive nitric 
oxide (NO) formation and mitochondrial dysfunction (von Bohlen und Halbach et al. 
2004). 
Increased activity of glutamate in the STN has been reported in animal models 
and post-mortem studies (Symeyne and Jackson-Lewis 2005). MPTP induced animal 
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models of PD have shown altered glutamate activity, while co-injection of MPTP with 
glutamate antagonists offered protection to DA neurons from the deleterious effects of 
glutamate (Symeyne and Jackson-Lewis 2005). 
1.7.4 Neuroinflammation in PD 
The role of inflammation in neurodegenerative diseases such as PD is not well 
understood and the events triggering an inflammatory response in the brain are unclear. 
Glial cells are the most abundant cells in the brain and make up 90 percent of the cells 
in the brain. These cells do not carry nerve impulses. However, they perform many 
important functions, including providing physical and nutritional support for neurons. 
Different types of glial cells exist, which include Microglia, Oligodendroglia, Astroglia, 
Schwann's Cells, and Satellite Cells (Mena and De Yebenes 2008). 
Astrocytes are the most abundant glial cells, and are considered to be critical for 
neuronal support, nutrition, eliminating toxic compounds, and production of neurotrophic 
substances. Astrocytes are of interest to PD researchers because PD patients have a lower 
number of astrocytes in the substantia nigra (SN) than in other brain areas (Mena and De 
Yebenes 2008). It is hypothesized that DA neurons of the SN region have increased 
susceptibility to toxic insults because they are less protected than neurons of other 
regions. DA neurons spontaneously produce free radicals during the metabolism of 
dopamine, and the astrocyte guardian cells that offer protection from oxidative stress 
have high free radical scavenging properties (Mena and De Yebenes 2008). Indeed, there 
is evidence to suggest that astrocytes support the differentiation, survival, 
pharmacological properties, and resistance to injury of DA neurons. Dysfunctional 
26 
astrocytes enhance neuronal degeneration by a diminished secretion of trophic factors. 
Glial cells can also instigate damage of nigrostriatal DA neurons via the release of 
cytokines and amplified production of reactive oxygen molecules (Mena and De Yebenes 
2008). 
Over the last decade the concept of "neuroinflammation" has become more 
accepted in the field of neurodegenerative diseases, and particularly in PD (Mena and De 
Yebenes 2008). There is an abundance of reactive astrocytes and reactive microglia in the 
SN of PD patients, indicating a robust inflammatory state (Mena and De Yebenes 2008). 
Glial cells are normally neuroprotective but given adverse stimulation, they may possibly 
contribute to chronic inflammation. Microglia, the phagocytes of brain, might be the main 
contributors of inflammation as they can produce large amounts of superoxide anion 
radicals and other neurotoxins (Mena and De Yebenes, 2008). Oligodendrocytes do not 
seem to play a part in promoting inflammation but may be sensitive to damage by 
inflammatory processes (Mena and De Yebenes 2008). 
In PD, degeneration of dopaminergic neurons is coupled with a drastic increase in 
microglial activity, which could be a consequence of neuronal cell death or due to 
participation of microglia in the cell death process (McGeer and McGeer 1999). Altered 
glial function contributes to the demise of DA neurons as observed upon co-incubation of 
these neurons with toxins such as MPTP and 6-hydroxydopamine (6-OHDA) (McNaught 
and Jenner 1999). The detection of elevated levels of pro-inflammatory cytokines and 
increased oxidative stress induced damage in post mortem PD patient samples suggests 
that microglial activation plays a significant role in the degenerative process leading to 
PD (Teismann and Schulz 2004). 
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McGeer et al. reported that the response of glial cells is more robust in the SN 
than the striatum, albeit damage to DA neurons is more severe in the striatum (1999). 
Microglia become activated in the brain, proliferate and start expressing noxious 
molecules such as ROS, RNS, cytokines and pro-inflammatory prostaglandins in 
response to various insults (Kreutzberg 1996). Amplified levels of pro-inflammatory 
cytokines such as tumor necrosis factor alpha (TNF-a) and interleukin-ip (IL-ip) have 
been observed in the cerebrospinal fluid and striatum of PD patients (Mogi 1994). These 
cytokines are potent activators of inducible nitric oxide synthase (iNOS) in rodents 
(Teismann and Schulz 2004). Cytokines released from glial cells bind to their specific 
receptors found on DA neurons. Upon binding to their corresponding receptors, these 
cytokines can trigger apoptosis by activating caspase-3 via the extrinsic pathway 
(Hartmann et al. 2000) 
All of these cellular events play an important role in the progression of PD. There 
is a complex inter-relationship that exists, making it is very difficult to elucidate the 
initiating event. 
1.8 Advances in Therapeutic Approaches for PD 
There are several options available for the potential treatment of PD. Current 
therapies are symptomatic and focus on treating the symptoms of PD. These include 
dopamine replacement strategies, non-dopaminergic pharmacological therapies, surgical 
approaches (directed at improving motor function, or at replacing striatal 
dopamine/dopaminergic neurons), and neuroprotective therapies. Undoubtedly, these 
therapies have significantly improved the quality of life and survival of PD patients; 
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however, with disease progression clinical features emerge that cannot be controlled 
with available medical or surgical therapies (Olanow 2008). The development of a 
neuroprotective therapy that slows, impedes, or ideally reverses neurodegeneration 
occurring in Parkinson's disease is a most important and fruitful area of research but 
also the area most abounding in failures (Lang and 0beso2004b). 
Surgery is an option held in reserve for complex cases of PD in which motor 
complications or medical intolerance has led to a drastic decline in quality of life (Savitt 
2006). Surgery for Parkinson's disease may involve destruction of certain parts of the 
brain (thalamus, the globus pallidus and the subthalamic nucleus) or insertion of 
electrodes into these areas for electrical stimulation. Cell transplantation to replace 
striatal DA neurons is under investigation even though there are many technical and 
methodological issues (Lang and 0beso2004b). Many studies in rodents indicate that 
embryonic mesencephalic cell grafts can survive, reverse dopamine deficit and even 
compensate for the behavioural disturbances arising from depletion of dopamine. Clinical 
trials using embryonic mesencephalic cell grafts on PD patients have increased survival 
and can secrete dopamine in response to pharmacological stimuli (Lang and 
0beso2004b). 
Pharmacological replacement of dopamine with dopamine agonists, such as 
Levodopa (L-dopa), is the most effective symptomatic treatment for PD (Olanow 2008). 
Although L-dopa is extremely effective; there are two main concerns with its long-term 
use. The first relates to the toxicity of L-dopa to dopamine neurons; L-Dopa can generate 
harmful reactive oxygen species (ROS) by oxidative metabolism of dopamine or via 
autooxidation, which may hasten the rate of degeneration in PD. The second concern is 
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the high frequency of motor complications associated with chronic L-dopa treatment 
(Olanow 2008). 
There is ample evidence for the role of inflammation in PD. Numerous case-
control studies suggest that people who use non-steroidal anti-inflammatory agents have a 
lower risk of developing PD. Many neuroprotective agents such as monoamine oxidase 
(MAO-B), inhibitors such as rasagiline, anti-excitatory drugs such as glutamate 
antagonists, and trophic factors such as GDNF have been studied for their potential as 
possible therapeutics (Olanow 2008). Bioenergetic compounds such as creatine, 
riboflavin, nicotinamide and Coenzyme Qio (C0Q10) are potential candidates as 
neuroprotective agents for PD (Beal, 2003b). 
1.8.1 CoQio as a Neuroprotective Agent 
Coenzyme Qio (CoQio) is a hydrophobic, naturally occurring compound that 
transfers electrons from complex-I and complex-II to complex-Ill of the mitochondrial 
electron transport chain. It is a very important antioxidant in the mitochondria as it 
readily scavenges free radicals (Beal 2003b). The redox cycling of CoQio is shown in 
figure 1.10. CoQio also called ubiquinone can accept one electron and form a 
semiubiquinone radical, which can then accept one more electron to get reduced to 
ubiquinol. 
Neuroprotective effects of CoQio in the central nervous system have been 
demonstrated in vivo by the prevention of reduction in the GSH and ATP levels, as well 
as protection during experimental ischemia (Beal 2003b). An open-label phase trial of 
CoQio in PD patients found good CoQio absorption and tolerability. Although 
30 
encouraging results were obtained from this study, Beal and his colleagues have 
cautioned that the data is preliminary and would only recommend that PD patients take 
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Figure 1.10 The oxidized and reduced forms of C0Q10. The oxidized form of C0Q10 
(ubiquinone) can accept one electron to form the semiubiquinone radical, which can 
accept one more electron to form the reduced form of C0Q10 (ubiquinol). 
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A major drawback in working with C0Q10 is that it is very lipophilic and so 
studying its protective properties in cell culture is difficult due to its hydrophobic nature; 
however, through a patented protocol (US patent #6 045 826) a water-soluble formulation 
of CoQio (WS-CoQio) was developed by Sikorska and Borowy-Borowsky of the National 
Research Council of Canada. Vitamin-E and polyethylene glycol have been used as 
carriers to solubilize CoQio and help in the uptake of this compound by the cells. Studies 
aimed at evaluating the bioavailability of this formulation established that cells were 
capable of internalizing WS-CoQio when it was added to the media as an aqueous 
solution (Borowy-Borowski et al. 2004). A 3-day exposure to 10 ng/ml of WS-CoQio, 
caused an increase in cellular mitochondrial membranes and cell membranes. The 
treatment also caused an increase in total cellular levels of ATP (Sandhu et al. 2003).This 
formulation has effectively been used to prevent oxidative stress induced cell death 
(McCarthy et al. 2004, Somayajulu et al. 2005). Protection by WS-CoQio of 
differentiated neuronal cells against cell death induced by glutamate excitotoxicity was 
also reported (Sandhu et al. 2003). Recently, WS-CoQio was shown to inhibit Bax 
activity and thus prevent Bax-induced destabilization of mitochondria in mammalian 
cells (Naderi et al. 2006). I have shown WS-CoQio to be protective against PQ-induced 
toxicity in vitro; therefore evaluatation of the efficacy of WS-CoQio in vivo was the next 
step. This project is focussed on evaluating the efficacy of this unique formulation of 
CoQio in preventing dopaminergic (DA) cell death occurring in PD. 
Studies in my lab have shown that PQ induces neuronal cell death (McCarthy et 
al. 2004) and pre-treatment of these cells with WS-CoQio can prevent PQ mediated cell 
death in vitro. I have tested the efficacy of this compound in two different cell lines and 
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using different insults. The results from the in vitro work were very encouraging and 
therefore roused interest to test the efficacy of this compound in vivo. 
As mentioned earlier, occurance of sporadic PD is correlated with exposure to 
toxins. Toxin induced PD model could be a good model to study the efficacy of the water 
soluble formulation of CoQio- As described before, many mice models of PQ induced PD 
are used, but there is a lack of behavioural outcomes in these models. I wanted to 
establish a model to assess the deficits in motoer and balancing behaviour. This project is 
a collaborative work between the department of Biochemistry and Pschology at the 
University of Windsor, Ontario. Dr. Cohen, our collaborator has a well established 
pschology lab where he uses rats to study different behaviours. Since there exists a 
functional lab to assess behavioural outcomes in rats, they were the ideal choice for a 
sporadic PD model for this study. 
Previous work has shown that PQ causes oxidative stress induced cell death of 
DA neurons and WS-C0Q10 helps prevent this loss of neurons. PQ induces selective loss 
of dopaminergic iof the neurons in the SNc. Toxin-induced sporadic models of PD have 
been developed, where exposure to toxins such as herbicides can lead to the loss of 
dopaminergic neurons in the SNc. PQ-induced PD models have been well characterised 
in mice (McCormack et al. 2002) in which the neurodegenerative changes induced by PQ 
are dose-dependent and differentially affect specific cell populations (McCormack et al. 
2002, Manning-Bog et al. 2003). Our working hypothesis was based on the fact that PQ 
induces death of DA via oxidative stress and mitochondrial dysfunction. WS-CoQio can 
prevent mitochondrial dysfunction as observed in in vitro studies previously. If animlas 
are fed with this formulation, it can provide resistance aginst PQ mediatd toxicity. Since a 
behavioural component is used to assess motor damage, PQ mediated DA degeneration 
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would lead to motor and balance deficits. If WS-C0Q10 is neuroprotective, it would result 
in redox balance favouring low oxidative stress, decrease the number of DA neurons 
undergoing cell death, and ultimately reduce the motor and balance deficits induced by 
PQ. 
1.9 Objectives 
The objectives of this research are to: 
1. Develop a paraquat-induced sporadic Parkinson's disease model in Long Evan's 
hooded rats. 
2. Assess the neuroprotective effects of water soluble Coenzyme Qio (WS-CoQio) 
by evaluating behavioural, biochemical and histochemical parameters and to 
evaluate the mechanism of neuroprotection offered WS-CoQio. 
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Chapter 2 
Materials and Methods 
2.1 Animals and General Supplies 
Long-Evans hooded rats were purchased from Charles River Breeding Farms in St. 
Constant, Quebec. Superfrost slides were purchased initially from VWR (catalogue 
number 48311-703) and recently from Fisher (catalogue number 12-550-18, 12-550-
16A); tissue embedding rings (catalogue number 25602-766) and paraffin (catalogue 
number 72050-030) were purchased from VWR. Square glass Coplin jars with lids that 
hold 10 slides were a gift from NRC Ottawa. Brain matrix for coronal sectioning for an 
adult rat weighing between 300-600 g (catalogue number 15054) was purchased from 
Ted Pella Inc. Disposable microtome blades (catalogue number DMB-LP) were 
purchased from Triangle Biomedical Sciences. Antibody diluent (catalogue number 
S0809) and blocking solution (catalogue number X0909) were purchased from DAKO. 
Ultracruz mounting medium for fluorescence (catalogue number B2808) was purchased 
from SantaCruz Biotechnology. Cytoseal™ 60 (catalogue number 8310-16) was obtained 
from Richard-Allan scientific. 
2.2 Stains, Kits and Antibodies 
Hematoxylin mercury-free acidified solution (catalogue number 245-677) was 
purchased from Fisher and Eosin Y alcoholic saturated solution (catalogue number 1502-
130) was purchased from VWR. Cresyl Violet acetate (catalogue number C1791) and 
Diamino benzamidine (DAB) (catalogue number D8001-5G) were purchased from 
Sigma. Luxol fast-blue and FD-Neurosilver kit (PK 301) were purchased from FD 
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Neurotechnologies. Fluoro-jade B (catalogue number AG310) was bought from 
Chemicon. Peroxidase substrate kit (catalogue number SK- 4100) was purchased from 
Vector laboratories. 
Primary antibodies: Rabbit anti-Tyrosine Hydroxylase polyclonal antibody 
(catalogue number P40101-0) was purchased from Pelfreeze, and mouse anti-tyrosine 
hydroxylase monoclonal antibody (catalogue number T2928) was bought from Sigma. 
Rabbit anti-dopamine transporter polyclonal antibody (catalogue number AB1591P), 
rabbit anti-vesicular monoamine transporter 2 c-terminus polyclonal antibody (catalogue 
number AB1767), rabbit anti-glial fibrillary acidic protein polyclonal antibody (catalogue 
number AB5804), rabbit anti-synuclein polyclonal antibody (catalogue number AB5038), 
rabbit anti-parkin polyclonal antibody (catalogue number AB9244) and mouse anti-NeuN 
clone 60 Alexa Fluor 488-tagged monoclonal antibody (catalogue number MAB377X) 
were purchased from Chemicon. Rabbit anti-4-hydroxy nonenal polyclonal antibody 
(catalogue number 393207) was purchased from VWR. Rabbit anti-nitrotyrosine 
polyclonal antibody (catalogue number A-21285) and Apo-brdU TUNEL assay kit 
(catalogue number SKU#A23210) were purchased from Molecular Probes. 
Secondary antibodies: Polyclonal goat anti-rabbit HRP conjugate (catalogue 
number P0448) was purchased from DAKO; Anti-Rabbit IgG (whole molecule) FITC 
antibody produced in sheep (catalogue number F7512) and anti-mouse IgG (whole 
molecule) peroxidase conjugate (catalogue number A9044) were purchased from Sigma. 
2.3 Reagents for Biochemical Assays 
For Adenosine 5'-triphosphate (ATP) assay: lyophilized luciferin luciferase mix 
(catalogue number FLAAM-1VL) was purchased from Sigma and ATP (catalogue 
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number 93168322) was purchased from Roche. For reduced glutathione (GSH) assay: 
GSH (catalogue number G-6529), Glutathione reductase (GSR) (catalogue number 
G3664-500U) and DTNB (catalogue number D8130) were purchased from Sigma. The 
proteome profiler rat cytokine array kit (catalogue number ARY008) was purchased from 
R&D systems. For protein assays: Bovine serum albumin (BSA) (catalogue number 
A7906) was purchased from Sigma and Bio-Rad protein dye assay reagent concentrate 
(catalogue number 500-0006) was purchased from BIORAD. For lipid peroxidation 
assay: tricholoro acetic acid (catalogue number T9159) and 2-thiobarbituric acid 
(catalogue number T5500) and the MDA standard (1,1,3,3-tetramethoxypropane) 
(catalogue number 108383) were purchased from Sigma. For SDS-PAGE and western 
blotting: TEMED and bis-acrylamide were purchased from BIORAD; Tris-HCl, Glycine, 
Tris-base and SDS were purchased from BD. Nitrocellulose membranes (catalogue 
number 66485) were purchased from PALL Gelman Labs; low fat milk powder, Nestle 
Carnation brand, was purchased from Canadian Tire. Chemiluminescent peroxidase 
substrate (catalogue number CPS-160KT) was purchased from Sigma. 
2.4 Water-soluble CoQio and Placebo 
2.4.1 Water-soluble Formulation of Coenzyme Qi0 (WS-CoQio) 
The WS-CoQio and placebo solution used in this experiment were supplied by 
NRC Ottawa. The WS-CoQio was produced through a patented protocol (US patent #6 
045 826) and contains both oxidized and reduced forms of CoQio in a 2: 1 (w/w) ratio. 
Coenzyme Qio (CoQio) is contained within a water soluble "cage" made of polyethylene 
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glycol and a-tocopherol (vitamin E). This water-soluble formulation was prepared from 
C0Q10 (Kyowa Hakko, New York, NY) and polyoxyethanyl a-tocopheryl sebacate (PTS) 
by directly combining both components in a molar ratio of 1: 2 mol/mol (1:3 w/w) and 
heating them to a temperature higher than their respective melting points to form a clear 
melt, which is water-soluble and can be diluted with aqueous solutions (e.g., phosphate 
buffered saline (PBS), water, saline) to a desired concentration as previously described 
(Borowy-Borowski et al. 2004) , (www.Zvmes.com). 
2.4.2 PTS or Placebo 
PTS/placebo was synthesized by conjugating polyethylene glycol 600 to a-
tocopherol via bi-functional sebacic acid (Sigma-Aldrich, St. Louis, MO) as previously 
described (Borowy-Borowski et al. 2004), (www.Zymes.com). Typically, stock solutions 
of WS-CoQio (50 mg of CoQio and 150 mg of PTS per ml in PBS) or a placebo (150 mg 
of PTS per ml of PBS) were made and stored at 4°C. These samples were then shipped to 
Dr. Pandey at the University of Windsor. Stock solutions were diluted with regular 
drinking water to a final concentration of 50 |ig WS-CoQio and 50 (ig PTS per ml 
(placebo) for the experiments. 
2.5 Instruments 
A Genesys 10UV Spectrophotometer was used for measuring absorbance for 
Bradford assays and lipid peroxidation assays. Centrifugation was performed using CR3i 
Jouan centrifuge (fixed angle rotor: 13,000 r.p.m. (12520 xg) and swing bucket rotor: 
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4,000 r.p.m. (3023 xg)), DESAGA Starstedt-Gruppe centrifuge and Biofuge 15 centrifuge 
from Baxter Scientific Inc. A SpectraMax GEMINI XPS from Molecular Devices was 
used for luminescence (ATP assay) and fluorescent assays. The chemidoc from ALPHA 
INNOTECH Corporation was used for gel imaging. Microscopes from MOTIC AE20 
(attached to a Moticam 2300 camera, 3.0 MP Live resolution), Leica DM IRB, Nikon 
ECLIPSE E800 (Dr. Zielinski's lab), ZIESS Axioskop 2 mot plus and (Dr. Crawford's 
lab) were used for taking phase and fluorescent pictures. Microtomes from American 
Optical Company (Dr. Crawford's lab) and MICROM HM 320 were used for sectioning. 
Sorvall tissue grinder was used for homogenizing tissues. ELx808 IU Ultra microplate 
reader from BIO-TEK INSTRUMENTS, Inc. was used for measuring absorbance in 96 
well plates. Labconco freeze dry system/freezone 4.5 lypholizer was used for 
concentrating samples. Other general laboratory equipments used included the following: 
A pH meter (Beckman, <E>310) with buffer solutions from ACP, an Adventurer™ 
balance and Scout ™ Pro balance (OHAUS), Vortex GVLab from Gilson(R) Industries 
Inc., a 1296-002 DELFIAR plate shaker from Wallac, a Gibco BRL heatblock from 
VWR, a Rocking platform model 200 from VWR, a Corning stirrer from Fisher 
Scientific, a Sorvall OMNI-MIXER, a BIORAD Power Pac 200 and Eppendorf pipettes 
from Fisher Scientific, VWR, and Gilson. 
2.6 Animal Care 
Twenty five male Long-Evans hooded rats (60-90 days old) were purchased from 
Charles River, Quebec. Upon arrival, the rats were randomly split into two groups: those 
that would receive injections of PQ and those that would receive injections of saline. 
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These two groups were further divided into groups based on their water regimen: whether 
they received WS-CoQio (50 (ig/mL), or placebo (50 jig/mL) in their drinking water or 
plain drinking water. Throughout the experiment, developmental changes were made to 
the model involving group division depending on water supplementation. The average 
rate of water consumption for a rat is 10 ml per 100 g of body weight each day. At this 
rate, an average sized rat (500 g) consumed 5 mg of either WS-CoQio or placebo per day. 
Each one of the groups was housed in separate cages, which can hold between 
four to five rats. During the weekdays, rats were placed in individual cages, fed 20 - 25 g 
of rat chow, and given two hours to consume their meal. During the weekends, rats 
remained in group cages and received group feedings. Plain water or water supplemented 
with either WS-CoQio or placebo was available to the rats every day. On this feeding 
schedule, the rats were kept at 90% of their normal, free-feeding weights verified through 
weekly weighing. Given that rats are nocturnal, to ensure that they were awake during 
the day for behavioural testing, the rats were kept on a reversed 12 h: 12 h light: dark 
cycle with the temperature maintained at 20°C. All animal care, treatments, and 
procedures were approved by the University of Windsor's Animal Care Committee 
(AVPP060010706) in accordance with the Canadian Council for Animal Care guidelines. 
Please refer to Appendix A for further details on injecting animals. 
2.7 Injection Regimes 
2.7.1 Three Injections of PQ 
Two different experimental designs were used for the three injection study. 
Figure 2.1 describes the time-line and group allocation for both experiments. Previous 
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studies have used three intraperitoneal injections of PQ (10 mg/kg) to induce selective 
damage to dopaminergic neurons in the SN in mice; we used a similar protocol in rats 
(McCormack et ah 2002). 
Experiment #1: Sixteen naive adult male Long-Evans hooded rats were used in 
the first experiment, designed to establish the regimen of PQ-injections, the degree of 
neurodegeneration and potential neuroprotection by WS-CoQi0. Figure 2.1 A outlines the 
procedures applied in this experiment: three weeks prior to the first saline or PQ injection 
(and for the duration of the experiment) the rats received either plain water or water 
supplemented with WS-CoQio or placebo. The rats were given three weekly 
intraperitoneal injections of PQ (10 mg/kg body weight dissolved in saline) or saline. The 
rats were further divided according to the treatments they received: one group received 
saline injections and plain water; a second group received PQ injections and plain water; 
a third group received PQ injections and drinking water supplemented with placebo and 
the fourth group received PQ injections and WSCoQio supplemented drinking water 
(Figure 2.1 A). Since placebo (PTS) is a pro-drug form of vitamin E (in which tocopherol 
was chemically derivatised by sebacic acid and PEG) that is used as a component 
(carrier) of the WS-CoQio formulation (Sikorska et ah 2003), the effect of WS-CoQio 
was compared to placebo and water treated groups. Rats were sacrificed one week after 
the last injection and the brains from these rats were extracted, fixed in formaldehyde. 
This experiment was repeated with sixteen rats. For this set of rats, biochemical 
parameters were performed for 2 rats from each group. 
Experiment #2: Twenty-five naive adult male Long-Evans hooded rats were used 
for this experiment and were exposed to a similar injection schedule as in Experiment 1. 
The PQ-induced neurodegenerative and WS-CoQio neuroprotective effects that resulted 
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from Experiment 1 prompted us to conduct a second experiment (Figure 2.IB) which is 
modified not only to assay histological/biochemical parameters of PQ-induced 
neurodegeneration, but also to determine PD-like behavioural changes from such 
exposure and to determine whether WS-CoQio treatment could prevent PQ-induced 
behavioural impairment. Due to the fact that no significant differences in nigral neuronal 
counts were observed between the PQ-Placebo and PQ-Water treatment groups in 
Experiment 1, we eliminated plain water treatment from Experiment 2, and gave the rats 
either WS-CoQio or its carrier solution (Placebo) in the drinking water. Thirteen rats that 
received drinking water supplemented with WS-CoQio and were divided into two 
injection groups: Saline-CoQio (n=6) and PQ-CoQio (n=7). Twelve rats that received 
placebo supplemented drinking water were divided into two groups based on the injection 
regime: Saline-Placebo group (contained six rats) and the PQ-Placebo group (contained 
six rats). Rats were sacrificed two weeks after their last injection as opposed to one week 
in experiment 1. This additional week allowed us to carry out post-injection behavioural 
assessment of gait performance on the rotorod apparatus. Three rats from each group 
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Figure 2.1 Schematic outlines for the three injection PQ regime. (A) Experiment 
1 scheme. (B) Experiment 2 scheme. 
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2.7.2 Five Injections of PQ 
Since eight injections proved to be very toxic to rats, we decided to see if five 
injections of PQ would achieve a greater neuronal loss than the three injection regime. 
After arrival, rats were randomly grouped and subjected to three weeks of behavioural 
testing to establish a baseline of their motor abilities (Figure 2.2). Following this, the rats 
were injected once a week for five weeks giving a total of five injections. After 
conducting the post injection behavioural studies the rats were dissected and tissues were 
collected for various experiments. This regime was followed for two sets of experiments: 
One to study the prophylactic versus therapeutic effects of WS-C0Q10 and two, to 
compare the effects of PQ between old and young rats. 
| Regular drinking water, or water supplemented with placebo or WS-CoQ,g | 
1 weekly 





















Perfusion, dissection and 
collection of brain and other 
tissues 
Figure 2.2 Timeline for five injection regime. 
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2.7.2.1 Prophylactic vs. Therapeutic Effects of WS-C0Q10 
In order to study the effects of various neuroprotective agents, they are either 
administered before inducing the disease condition (prophylactic use) or after inducing 
the disease condition (therapeutic). To design an experiment to study the prophylactic and 
therapeutic effects of WS-C0Q10, 24 naive rats were divided into six groups. One group 
received intraperitoneal injections of saline. The other five groups received 
intraperitoneal injections of PQ (10 mg/kg). After the fifth injection, the drinking water 
for two of the five PQ-injected groups was changed in order to investigate the effects of 
WS-CoQIO administered after PQ-induced neurodegeneration. One of the two groups 
received WS-CoQIO supplemented water, starting immediately after the last injection 
(the next day), while the other received placebo (Table 1). The drinking solutions were 
prepared the same for all experiments. The behavioural assessments continued throughout 
the experiment to obtain post-injection measurements. Three weeks after the last 
injection, two rats from each group were sacrificed for biochemical analyses and two 
from each group were processed for histochemistry. This experiment was repeated with 
the same number of rats, groupings and water supplementation. 
Table 1. WS-CoQio feeding regime prior to and after injections of PQ. 
1 4 Saline Water 
Unchanged 
2 4 PQ Water 
3 4 PQ Placebo 
4 4 PQ WS-CoQio 
5 4 PQ Water Placebo 
CoQio 6 5 PQ Water 
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2.7.2.2 Old vs. Young Rats 
This experiment was designed to compare the effects of PQ-induced 
neurodegeneration in young versus old rats as well as to evaluate the neuroprotective 
effects of WS-C0Q10. Sixteen naive young rats (purchased between 60-90 days old) and 
16 old rats (purchased between 300-350 days old). The young and old rats were divided 
into four groups on the basis of injection and water regime (Table 2). The behavioural 
assessments continued in the pre-, mid- and post-injection phases. Two rats from each 
group were processed for histochemistry while the other two were used for performing 
biochemical analyses. This study is yet to be repeated. 
Table 2. Grouping young and old rats on the basis of injections and water regimen. 
1 4 Saline Water Young 
2 4 PQ Water Young 
3 4 PQ WS- CoQio Young 
4 4 PQ Placebo Young 
5 4 PQ Water Old 
6 4 PQ WS- CoQio Old 
7 4 Saline Water Old 
8 4 PQ Placebo Old 
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2.8 Tissue Harvesting for Brain Histochemistry 
The rats were placed into a plexi-glass chamber and anaesthetized with isoflurane 
until the rat was unresponsive to a noxious stimulus (i.e., pinched leg). Following this, an 
anaesthetic muzzle was placed on the rat and the rat was then transferred onto a 
dissection tray. An incision was made from the pelvis to the neck and both the pleural 
and thoracic cavities were opened. To perfuse the rat, a 12 gauge needle was inserted 
into the left ventricle of the heart. Tyrodes solution (B.76 g NaCl, 0.298 g KC1, 0.222 g 
CaCl2, 2.603 g HEPES, 1 g dextrose, 1 g NaHC03, 0.06 g Na2HP04*4H20 per litre) 
containing 1 U/ml heparin to prevent blood clotting, was gravity fed through the twelve 
gauge needle (Cassella et al. 1997). Once a noticeable discoloration of the liver was 
observed, the Tyrodes solution was exchanged for a PBS (8 g NaCl, 0.2 g KC1, 2.68 g 
Na2HP04-7H20 and 0.24 g KH2P04 in 800 ml water, pH=7.4) containing 10% 
formaldehyde. This perfusion which used 10% buffered formaldehyde was continued 
until a noticeable rigidity developed in the muscles of the rat. Following this, the lungs, 
heart, kidney, liver, spleen and brain of the rat were harvested and placed in 10% 
buffered formaldehyde for 24 hours at 4°C to fix the tissues. Following fixation the 
tissues were transferred to 70% ethanol and stored at 4°C. Please refer to Appendix B for 
further details. 
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2.9 Tissue and Slide Preparation 
2.9.1 Brain 
After harvesting and fixing the tissues, a 4 mm thick coronal section was cut out 
of the midbrain using a brain matrix for coronal sectioning for an adult rat. To prepare the 
brain tissue for slicing on the microtome, it was dehydrated and embedded in paraffin 
wax as described below. 
After removal from 70% ethanol, the brain tissue was moved through dehydrating 
solutions: 95% ethanol for 60 minutes; 100% ethanol for 60 minutes; Xylene for 30-45 
minutes; 50/50 (v/v) mixture of Xylene and paraffin wax for 45 minutes at 60°C; and 
finally 100% paraffin wax overnight at 60°C in a water bath. Please refer to Appendix D 
for more details. 
Once the tissues were embedded in paraffin, they were placed into metal moulds 
and left to cool for approximately three hours at room temperature. Coronal sections, 8 
jim thick, were cut across the entire SN region and processed for immunohistochemistry 
using a stereotaxic rat brain atlas. The sections were placed on slides and dried overnight 
in an incubator at 40°C. 
2.9.2 Peripheral Organs 
Dehydration and paraffin embedding of the peripheral organs was performed 
using the protocol as mentioned in Section 2.8.1. Using a microtome, 8 |xm sections were 
taken for immunohistochemical analysis. 
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2.10 Preparation and Staining for Immunohistochemistry of the Brain Tissues 
2.10.1 Using 3,3'-diaminobenzidine (DAB) 
Our DAB staining procedure was slightly modified from a previously used 
protocol. To begin immunohistochemistry, the tissues on slides were subjected to 
deparaffinization and rehydration. To deparaffinize, these slides were incubated in xylene 
for 20 minutes (2 x 10 minutes). To rehydrate, the slides were then incubated in 100% 
ethanol for 10 minutes; 95% ethanol for 10 minutes; 70% ethanol for 5 minutes; 
immersed in 50% ethanol; immersed in 30% ethanol; immersed in dH20; and incubated 
in 50 mM TBS (50 mM Tris-HCl, 150 mM NaCl, pH=7.6) for 5 minutes. The slides 
were then incubated for 30 minutes in methanol containing 3% H2O2 to block endogenous 
peroxidase activity of the tissue. The slides were then processed for antigen retrieval by 
incubation in 1 mM EDTA pH=8.0 heated to 95°C in a water bath for 20 minutes and 
then cooled for 20 minutes at room temperature. Finally, the slides were washed for 5 
minutes in 50 mM TBS, washed for 5 minutes in distilled water and incubated for 15 
minutes at room temperature with a universal blocking solution. Excess solution was 
removed and the slides were subjected to the primary antibody of interest in a humid 
chamber overnight at 2-8°C. The slides were then washed with TBS for 15 minutes (3x5 
minutes) and were subjected to the appropriate secondary antibody for 1 hour at room 
temperature and again washed in TBS for 15 minutes (3x5 minutes). Negative controls 
included the omission of primary or secondary antibodies. 
Immunolabelling was accomplished by using 0.02% diaminobenzidine 
tetrachloride and 0.006% H2O2 for 10 minutes at room temperature. Sections were 
washed in running water and counterstained with Mayer's hematoxylin for 90 seconds. 
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The slides were washed in TBS for 5 minutes to remove excess stain, and then immersed 
in a 0.2% HC1 in ethanol destaining solution followed by 10 dips in 10% NH4OH. The 
tissue was then dehydrated in 95% ethanol for 10 minutes; 100% ethanol for 10 minutes; 
and xylene for 10 minutes (2x5 minutes). The slide was then sealed with cytoseal and a 
cover slip. 
2.10.1.1 Tyrosine Hydroxylase (TH) Staining using DAB 
For the three injection regime, neurons were counted using DAB staining. 
Staining for TH using DAB began with the same steps as outlined in section 2.10.1. 
After blocking the slide for 15 minutes with blocking solution, the brain sections were 
incubated with rabbit polyclonal anti-tyrosine hydroxylase antibody (1:500, using DAKO 
antibody diluent) overnight at 4°C. These slides were washed in TBS for 15 minutes (3 x 
5 minutes), and then incubated for 1 hour at room temperature with goat anti-rabbit IgG 
peroxidase conjugated secondary antibody. The rest of the protocol was followed as 
outlined in 2.10.1. 
Loss of dopaminergic neurons (three injection regime) was determined by 
counting TH-immunopositive cells (cell body) under bright-field illumination. Sections 
were taken across the SN (bregma -5.04 mm to bregma -6.24mm) and stained for TH-
immunopositive neurons. The region for counting was delineated using a stereotaxic rat 
brain atlas. After delineation of the SNc using 10X objective, TH-immunopositive 
neurons were counted manually at different levels. The mean numbers of TH-
immunopositive neurons per section were calculated for each level. Analysis of the three 
injection regime was performed as a blind study where neurons were counted manually 
by two people. 
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2.10.1.2 Glial Fibrillary Acidic Protein (GFAP) Staining using DAB 
Staining for GFAP was performed by using a DAB-based detection protocol. 
Brain sections were incubated with rabbit polyclonal anti-GFAP (1:500, DAKO 
Cytomation Inc.) overnight at 2-8°C. Slides were washed (refer to 2.10.1) and the 
sections were subjected to secondary antibody conjugated to goat anti-rabbit IgG (1:500) 
for 60 minutes at room temperature. Immunolabelling was detected using DAB according 
to the protocol described in 2.10.1. This procedure is used by our collaborators at NRC 
Ottawa. 
2.10.2 Using Immunofluorescence 
A modified version of a previously published protocol was used (Thiruchelvam et 
al. 2000b). Briefly, tissue sections were deparaffinized in xylene for 20 minutes; 100% 
ethanol for 10 minutes; and incubated in TBS as described above. Non-specific IgGs 
were blocked with DAKO universal blocking solution for 15 minutes at room 
temperature. Excess liquid was removed and sections were incubated with primary 
antibody overnight in a humid chamber at 2-8°C and then washed with TBS as described 
above. Tissues were incubated with the appropriate secondary antibody tagged to 
fluorescein isothiocyanate (FITC) for 1 hour at room temperature and then washed for 15 
minutes in TBST and dehydrated in 95% ethanol for 10 minutes, followed by 100% 
ethanol for 10 minutes and then xylene incubation for 10 minutes (2x5 minutes). The 
slides were mounted with mounting media containing DAPI and the cover slips were 
sealed with clear fingernail polish. The slides were stored at -20°C. 
51 
2.10.2.1 Tyrosine Hydroxylase (TH) Staining with Fluorescence 
For the five injection regime, neurons were counted using immunofluorescence 
staining. Staining for TH began with the same steps as outlined in 2.10.2. After blocking 
the slides for 15 minutes with blocking solution, the brain sections were incubated with 
rabbit polyclonal anti-tyrosine hydroxylase antibody (1:500, using DAKO antibody 
diluent) overnight at 2-8°C. These slides were then washed in 50 mM TBS for 15 
minutes (3x5 minutes) and then incubated for 1 hour at room temperature with anti-
rabbit FITC conjugated secondary antibody (1:200 using DAKO antibody diluent). Next, 
the slides were washed for 15 minutes (3x5 minutes) in 50 mM TBS, mounted with 
mounting media containing DAPI and cover slips were sealed with clear fingernail 
polish. All slides were then stored at -20°C. Images were captured Nikon ECLIPSE 
E800, ZEISS Axioskop 2 Mot Plus or Leica DM IRB microscopes. 
For the analysis of the five injection regime, the SNc neurons were counted 
manually by two people: one person was familiar to the groups while the other was not. 
In this pilot study, evaluating the Prophylactic vs. Therapeutic effects of WS-CoQio, 
neurons were counted from two rats per group while in the five injection regime studying 
the effects of aging (Old vs. Young), neurons were counted from one rat per group. Every 
sixth section across the entire SNc was counted (both the left and the right sides) to 
obtain TH-immunopositive neuronal numbers. 
2.10.2.2 Glial Fibrillary Acidic Protein (GFAP) Staining with Fluorescence 
Staining for GFAP began with the same steps as outlined in 2.10.2. After blocking 
the slide for 15 minutes with blocking solution, the brain sections were incubated with 
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rabbit, monoclonal anti-GFAP antibody (1:500, using DAKO antibody diluent) overnight 
at 2-8°C. These slides were then washed in 50 mM TBS for 15 minutes (3X5 minutes) 
and then incubated for 1 hour at room temperature with anti-rabbit FITC conjugated 
secondary antibody (1:200, using DAKO antibody diluent). The slides were then washed 
for 15 minutes (3x5 minutes) in 50 mM TBS and then mounted with mounting media 
containing DAPI; the sides of the cover slip were sealed with clear fingernail polish. All 
slides were then stored at -20°C until before and after photography. For counting 
activated astrocytes, no particular parameters were set for this batch of experiments. 
However, it is recommended to set parameters that define activated conditions of 
Astrocytes. 
2.10.2.3 NeuN (neuronal nuclei) staining 
Staining for NeuN began with the same steps as outlined in 2.10.2. The 
manufacturer's protocol (Chemicon) was followed for antigen retrieval and antibody 
dilution. After incubation in 50 mM TBS for 15 minutes the sections were subjected to 
antigen retrieval using fresh lOmM sodium citrate (pH=6.0) for 20 minutes at 90°C in a 
water bath. Following this sections were allowed to cool down to room temperature for 
30 minutes. Next, the sections were washed with 50 mM TBS for 5 minutes and 
incubated with DAKO universal blocking solution for 15 minutes in a humid chamber at 
room temperature. Excess blocking solution was removed and slides were incubated with 
NeuN antibody (1:100, using antibody diluent) overnight at 2-8°C. The slides were then 
washed with 50 mM TBS and dehydrated, incubated with xylene and cover slipped using 
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mounting media containing DAPI and sealed with clear fingernail polish. All slides were 
then stored in -20°C. 
2.10.3 Hematoxylin and Eosin (H&E) Staining for Brain and Peripheral 
Histopathology 
The protocol was modified slightly from the original version obtained from NRC, 
Ottawa. The same protocol was used for staining the brain and peripheral tissues (lung, 
liver and kidney). Slides were subjected deparaffinization in xylene for 20 minutes (10 x 
2 minutes), rehydration in 100% ethanol for 10 minutes, 95% ethanol for 5 minutes, 70% 
ethanol for 5 minutes and dH^O for 5 minutes. The slides were stained with hematoxylin 
for 3 minutes, and washed in dl^O for 5 minutes. They were then immersed twice in acid 
alcohol (0.2 mL HC1 in 100 mL 70% ethanol) and rinsed with running water and dH^O. 
Slides were then incubated for about 1 minute in eosin, rinsed and washed in 95% 
ethanol, followed by 100% ethanol for 10 minutes each and finally immersed in xylene 
for 20 minutes (2x10 minutes). The slides were cover slipped using cytoseal mounting 
media. 
2.11 Tissue Fractionation of the Brain 
The rats designated for biochemical analysis (after completion of behavioural 
studies) were sacrificed by CO2 inhalation in accordance with a protocol approved by the 
Canadian Council for Animal Care. Briefly, isolated brains were washed with ice-cold 
PBS and placed on ice until further dissection. For the three injection regimes, the brain 
was further dissected into the frontal cortex, the midbrain and the striatum. Rats were 
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sacrificed and experiments were done on the same day. Therefore, fresh midbrain and 
striatum homogenates were used for the three injection assays. The tissues were weighed 
and homogenized in 10 volumes (10 ml buffer for lg tissue) of ice-cold homogenization 
buffer (50 mM Tris-HCl, 0.15 mM NaCl, 10 mM EDTA, 1% TritonX-100, 1 mM PMSF, 
1 |J.g/ml pepstatin A, 1 jig/ml leupeptin, pH=7.5) (Akita et al. 2001). The homogenates 
were centrifiiged for 10 minutes at 3,000 r.p.m using a Jouan CR3i centrifuge and a T40 
swing bucket rotor at 4°C. The nuclear pellet (and debris) was discarded and the 
cytoplasmic/cytosolic fraction (supernatant) was used for GSH analysis, lipid 
peroxidation, cytokine array and Westernblots. Half of this supernatant (obtained after 
centrifugation at 3000xg) was subjected to centrifugation again at 12,520 xg to separate 
the mitochondrial fractions that were used for ATP assay. 
Unless utilised immediately, the cytoplasmic fractions were frozen at -80°C in 
250 fj.1 aliquots. If the assay was performed on frozen lysate, then the lysate was subjected 
to centrifugation at 3000 r.p.m for 7-10 minutes at 4°C and the pellet was discarded, 
prior to being assayed. 
For the five injection regime, there was a slight modification after the dissection. 
Instead of utilizing the midbrain and the striatum, only the midbrain was utilized for all 
assays in this regime. Furthermore, instead of utilizing fresh homogenates, the midbrain 
tissues were snap frozen in liquid nitrogen and stored at -80°C in this regime, (refer to 
Appendix C). Later these tissue homogenates were prepared and cytoplasmic fractions 
were obtained as mentioned above. All the assays: GSH, lipid peroxidation, ATP, 
Western blots, Cytokine analysis were performed on cytoplasmic fractions. Please refer 
to the summary Table 4 at the end of this chapter. 
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2.12 Protein Estimation Using Bradford Assay 
The concentration of proteins present in the tissue homogenates was estimated 
using the protocol from BioRad Laboratories. The protein estimation was performed in 
duplicates by using 2 juil of each sample, 798 nl of dHhO and 200 jil of BioRad protein 
assay reagent to a total volume of 1 ml in plastic cuvettes. The mixtures were then 
vortexed and allowed to stand for 5 minutes at room temperature. The absorbance was 
then measured by using a Genesys UV-Visible Spectrophotometer at 595 nm. The 
standard curve was prepared by using 1 to 14 fxl of lmg/ml Bovine serum albumin (BSA) 
standard, 799 to 786 p.1 of dt^O and 200 jil of BioRad protein assay reagent. Graph Pad 
Prism software was used for data representation. 
2.13 Glutathione (GSH) Assay 
The GSH assay was performed using a slight modification of a previously 
published method (Baker et al. 1990). Briefly, 2 jal of the homogenate and 100 |il of 
reaction mixture (containing 1 mM NADPH and 100 units GSH reductase in distilled 
water) was added in a 96-well plate and then incubated for 20 minutes at 37°C. Following 
incubation, 100^1 of 1 mM DTNB (dissolved in 0.1 M PO4 buffer, pH=8.0) was 
incubated for 15 min at 37°C. Absorbance was measured at 412 nm using a Bio-tek ELx 
808ru Ultra Micro plate Reader. GSH levels were determined from the standard curve 
constructed by using 1 mM GSH. Results were expressed per microgram of protein. 
Protein concentration was measured using the BioRad protein assay reagent and bovine 
serum albumin was used as a standard as above. Graph Pad Prism software was used for 
data representation. 
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2.14 Lipid Peroxidation Assay 
The lipid peroxidation assay was performed as previously described (Cereser et 
al. 2001). Briefly, 100 |xl of the homogenate obtained from the midbrain was added to 
lml of thiobarbituric acid (7 g trichloroacetic acid, 0.185 g thiobarbituric acid, 12.5 ml 
0.25 N HCl in 37.5 ml dF^O) and incubated at 100°C on a heat block for 20 min. After 
cooling the tubes, absorbance was measured at 535 nm using a Genesys 
spectrophotometer. Lipid peroxidation levels were determined from a standard curve 
prepared using 100 juiM malondialdehyde (MDA). Results were calculated per microgram 
of protein. Protein concentration was measured using the BioRad protein assay reagent 
with bovine serum albumin as a standard. Graph Pad Prism software was used for data 
representation. 
2.15 ATP Assay 
ATP content was measured as previously described (Sandhu et al. 2003). Briefly, 
100 |nl of tissue homogenate was mixed with 100 (il luciferin-luciferase solution in a 
black 96-well plate and incubated for 30 minutes at 37°C and the bioluminescence was 
using a plate reader using a Spectra Max Gemini XS spectrophotometer at 560 nm. The 
amount of ATP produced was determined from internal standard curve prepared by using 
100 pM ATP standard solution. The final results were expressed per microgram protein. 
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2.16 SDS-PAGE and Western Blotting 
The SDS-PAGE and western blot protocols were slightly modified from the 
original protocol (Sambrook et al. 1989). All the western blots were conducted used the 
following protocol with variations in the primary and secondary antibody as needed 
[monoclonal anti-TH (1:1000), polyclonal anti-GFAP (1:1000), polyclonal anti-PARKIN 
(1:1000), or polyclonal anti-synuclein (1;1000), polyclonal anti-iNOS (1:500)]. Protein 
samples were resolved using a 10% SDS-PAGE. 20 jig of protein (per well) was mixed 
with 4 X loading buffer (50 mM Tris-HCl, pH=6.8, 100 mM dithiothreitol, 2% SDS, 
0.1% bromophenol blue and 10% glycerol), heated for 2 minutes on a heat block at 95°C 
and then centrifuged before being loaded onto the gel. The protein was transferred from 
the gel onto a nitrocellulose membrane which was subsequently blocked using a non-fat 
5% milk solution in TBS with 0.2% Tween (TBST) for 1 hour on a shaker at room 
temperature. Then blots were then stained with Ponceau S and the blots were scanned and 
recorded to ensure equal loading. The membrane was then incubated with the required 
primary antibody in 2% non-fat milk solution overnight at 4°C for 12-18hours. After this 
incubation period, the membrane was washed with TBST for 15 minutes, followed by 
three more five minute washes and finally incubated with secondary antibody (anti-
mouse IgG (whole molecule) or anti-rabbit (whole molecule) peroxidase conjugate) at a 
dilution of 1:3000 in 2% milk solution and incubated at room temperature on a shaker for 
Ih. Finally, the blots were then washed with TBST for 30 minutes (1x15 minutes, 3x5 
minutes) and developed using a ChemiGlow West kit according to manufacturer's 
protocol (Sigma Aldrich) and recorded using an Alpha Innotech Corporation Imaging 
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System. All the Western Blots were performed twice from tissue homogenates obtained 
from one animal in each group. 
2.17 Cytokine Array 
In order to assess the relative levels of multiple cytokines in rats undergoing 
various treatments, a cytokine assay was performed. Tissue homogenates were prepared 
according to a protocol provided with the kit from R&D Systems. Briefly, the mid brain 
was homogenized in PBS (pH=7.6) with protease inhibitors (1 (iM leupeptin, 1 |jM 
pepstatin A and 10 (iM PMSF) and 0.1% Triton-X-100. The samples (100 fig protein) 
were incubated with detection antibody cocktail for 1 hour at room temperature on a 
rocking platform. Meanwhile, the membranes were incubated with blocking solution for 
1 hour at room temperature, after which the sample/detection antibody mixture was 
applied onto the membranes and they were incubated on a rocking platform overnight at 
2-8°C. The membranes were washed with Wash buffer for 30 minutes (3x10 minutes). 
After blotting excess wash buffer the membranes were incubated with Streptavidin-HRP 
and incubated for 30 minutes. The membranes were then washed for 30 minutes and 
incubated with chemiluminescent reagent in accordance with the manufacturer's 
protocol. The images were recorded with an Alpha Innotech Corporation Imaging 
System. Data was obtained from two rats in each group belonging to the five injection 
regime. 
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2.18 Behavioural Assessment 
2.18.1 Rotorod Apparatus 
We measured rats' ability to maintain their balance on a rotorod as per a 
previously described protocol (Winer, 1978). This rotorod apparatus consisted of a paper-
covered (80 grid) 15 cm long, 7 cm diameter wooden dowel attached to a variable speed 
motor. Clockwise revolutions of the rotorod could be adjusted from 6 to 12 R.P.M. The 
rod was separated from the motor by a vertical 30 x 48 cm grey wooden panel that was 
scored with black vertical and horizontal lines to form 12 x 12 cm squares as shown in 
Figure 3.7B. The apparatus rested on a small table so that the dowel was 27 cm above its 
surface. A digital video camera (Orbyx Electronics Inc, CA) was positioned 1 m in front 
of and level with the rod. The apparatus was illuminated by regular fluorescent ceiling 
lighting and a 60-W lamp approximately 3 m in front of it. 
Experiment 2 setup consisted of a two week pre-injection phase followed by an 
injection phase of three weeks and a two-week post-injection phase. Rats received three 
rotorod sessions during the pre-injection phase, spaced approximately two days apart 
over the two-week period, one rotorod session five days after the second injection (mid-
injection test), and one session in the post-injection phase given one week after their last 
injection. The first two pre-injection sessions served to train the rats to maintain their 
balance on the rotorod and gradually its rotation speed from 6 to 12 R.P.M was increased. 
From the third test on, the rotorod's rotation speed was maintained at 12 R.P.M. Rats' 
performance on the third pre-injection test provided baseline performance for comparison 
with the next two tests. Rats were always placed in the forward position (facing left) as 
the rod rotated clock-wise. 
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2.18.2 Dependent Behavioural Measures and Statistical Analyses 
Each rat's video recording was converted to 5 frames per second still pictures 
from which we recorded its movements over the last 100 seconds (500 frames) with a 
software tracking program (7 Software, Inc, Montana, U.S.A.). Figure 3.7B illustrates a 
picture frame superimposed on the tracking frame composed of 450 vertical and 450 
horizontal pixels. It was noted that although rats were initially oriented to walk forward 
on the slowly rotating rotorod, they also turned around and walked backward during 
some portions of these sessions. Therefore, we calculated the amount of time each rat 
actually spent (proportion of frames) walking backward as well as its average horizontal 
and vertical nose locations as it walked in each direction. 
Each rat's proportion of time spent walking backward was transformed into an 
arcs in 2^X measure to enhance homogeneity of variance for parametric statistical 
analysis of proportion scores (Whishaw et al. 2003). Each dependent measure was 
analyzed by 2 (Injection: PQ vs. Saline) by 2 (Liquid Supplement: CoQio vs. Placebo) by 
3 (Rotorod Test Session: pre-, mid-, post-injection) analysis of variance (ANOVA) with 
repeated measures on the last factor. We conducted statistical analyses of the behavioural 
data with SPSS (version 17) program and report significant effects at p <0.05. 
2.19 Statistical Analysis 
Unless otherwise stated, all the biochemical data are represented as the mean ± 
SEM of three independent animals; each assayed in triplicate. For the statistical analysis 
of the histochemical data, three animals have been used unless stated otherwise. A value 
of P<0.05 is considered as statistically significant. Two way ANOVA tests followed by 
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post-hoc Bonferroni's multiple comparisons test was used to assess statistical differences 
were performed using S.P.S.S software version 17 for three injection regime of PQ. Since 
the five injection studies were preliminary, no ANOVA was performed. 
T-tests were performed using Statistica 7.0 software for all the in vitro studies. 
2.20 Experiments Designed to Study the Mechanism of Neuroprotection by WS-
CoQio 
2.20.1 Cell Culture 
2.20.1.1 Human Neuroblastoma Cells or (SH-SY5Y cells) 
SH-SY5Y cells were grown as per manufacturer's protocol (ATCC) in Ham's F12 
medium (Gibco) with 2 mM L-Glutamine that was modified to contain 1.5 g/L sodium 
carbonate, 10% Fetal Bovine Serum and 10 mg/ml gentamycin at 37°C at 5% CO2. The 
cells were sub cultured by splitting 1:5 once a week. 
2.20.1.2 Transformed Human Embryonic Kidney Cells (HEK 293 cells) 
Cells were grown according to manufacturer's protocol (ATCC) using DMEM/F-
12 media (Sigma). The media were supplemented with 15% (v/v) Fetal Bovine Serum 
(FBS) in tissue culture flasks and/or Petri dishes and incubated in 5% CO2 at 37°C and 
95% humidity. 
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2.20.2 Measurement of ROS Production from Isolated Mitochondria of SHSY-5Y 
cells and HEK 293 cells 
SH-SY5Y cells were grown, and intact mitochondria were isolated as previously 
described (Li et al. 2003). Cells were harvested by mechanical dislodging using a rubber 
policeman and centrifuged at 500 x g for 5 minutes. They were washed twice with ice 
cold PBS and centrifuged at 250 x g, the cells were re suspended in isolation buffer 
containing 1 mM EDTA, 10 mM HEPES (pH= 7.4) and 250 mM sucrose. Cells were 
homogenized by a Dounce homogenizer with 20 strokes. The disrupted cells were 
centrifuged for 5 minutes at 600 x g at 4°C. The supernatant was collected and 
centrifuged at 15,000 x g at 4°C for 5 minutes and the resulting pellet was mitochondria. 
The pellet was re-suspended in buffer without EDTA. Mitochondrial suspensions were 
kept on ice and all the experiments were performed within 5 hours. For rotenone or PQ-
induced mitochondrial dysfunction, mitochondrial hydrogen peroxide was measured 
using p-hydroxy phenyl acetic acid (PHPA) by an increase in the fluorescence due to 
oxidized p-hydroxyphenylacetate fluorescence by horseradish peroxidase as previously 
described (Li et al. 2003). Total mitochondrial protein was estimated using BioRad with 
BSA as a standard. The reaction began by adding 50 |ig of mitochondria to a 100 )il 
reaction mixture containing 0.25 M Sucrose, 10 mM HEPES 10 ng/ml PHPA and 0.4 
units of HRP per well. In order to study the effects of WS-CoQio, 50 ng/ml CoQio was 
incubated with mitochondria for 30 minutes prior to addition of 10 |iM rotenone, or 200 
|j,M PQ. 10 mM succinate was added as a substrate and the contents were mixed. After 30 
minutes of incubation, the fluorescence of oxidized PHPA (excitation 320 nm, emission 
400 nm) was measured in a 96 well micro-titer plate using the Spectra Max Gemini XS. 
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Graph Pad prism 4.0 was used for data representation. This experiment was done in 
triplicate and repeated three times. 
For Bax-induced mitochondrial dysfunction, mitochondria were isolated from 
HEK 293 cells. The mitochondrial pellet, isolated as described above, was re-suspended 
in a reaction buffer consisting of 0.25 M sucrose, 1 mM MgCh, 10 mM HEPES, 100 mM 
succinate and 10 mg/mL PHP A. Mitochondria, were either untreated or pre-treated for 30 
min with 0.5 mg/mL WS-CoQio formulation. Following the 30 minute incubation with 
WS-CoQio, they were incubated with 5 (xg/mL of recombinant Bax for 5 minutes at room 
temperature. Control mitochondria were not treated with Bax. The mitochondrial 
suspensions (100 \iL per well) were placed in a 96 well plate and the wells were 
subsequently treated with 0.4 units of HRP and fluorescence was measured starting 
immediately after the addition of HRP for 10 min in 30-s intervals. The fluorescence 
readings were performed using the Spectra Max Gemini XS at an excitation wavelength 
of 320 nm and an emission wavelength of 400 nm. Microsoft excel was used for data 
representation. This experiment was done in triplicates and repeated thrice. 
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Table 4. Summary of the biochemical assays performed during different injection 
regimes. 
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This chapter is divided into three parts. The first part of the chapter focuses the 
results obtained from the initial studies with three injections of paraquat. The second part 
focuses on the specificity of paraquat treatment and evaluation of neuroprotection offered 
by WS-C0Q10 at higher doses of paraquat. The final segment focuses on deciphering the 
probable mechanism of neuroprotection offered by WS-CoQio-
3.1. Initial Studies with Three Injections of Paraquat 
This study was performed to evaluate: 
1. The toxicity of paraquat to the dopaminergic neurons. 
2. Neuroprotection offered by WS-CoQio against paraquat mediated toxicity. 
3.1.1. Effects of PQ on DA Neurons in the Midbrain and Neuroprotection by WS-
CoQio 
Many studies have used tyrosine hydroxylase (TH) immunostaining to estimate 
the number of dopaminergic neurons (McCormack et al. 2002, Peng et al. 2007). TH is 
an enzyme which converts the amino acid tyrosine into dihydroxyphenylalanine (DOPA). 




Tyrosine DOPA Dopamine 
Epinephrine 
Figure 3.1 Conversion of tyrosine to dopamine. Tyrosine is converted to DOPA by 
tyrosine hydroxylase (TH), which is the rate limiting enzyme. 
TH-immunostaining is used as a marker of choice since TH is the limiting enzyme 
for dopamine synthesis and is clearly reduced after dopaminergic insults (Emborg 2004). 
Examination of midbrain sections revealed a reduced TH-immunostaining in the 
PQ-injected rats (for Water-fed and Placebo-fed groups, Figure 3.2B and 3.2C 
respectively) as compared to the control Saline-injected rats (Figure 3.2A). There also 
was diminished staining of TH-positive fibres, indicating neuronal loss and reduced fibre 
density (compare Figures 3.2B-b'and 3.2C-c' to 3.2A-a'). 
In contrast, the images of the PQ-WS-C0Q10 midbrain sections showed strong 
TH-immunostaining of both the cell bodies and the fibres (Figure 3.2D and 3.2D-d'). 
This group of rats was given the WS-C0Q10 supplemented drinking water, which might 
have counteracted the effects of PQ. The immunostaining data was confirmed by 
counting the TH-immunopositive neurons in the entire SN region (Figure 3.2E). 
The counts revealed approximately 60% reduction of the number of cells in the 
PQ-injected rats receiving regular drinking water (from 313.7 ± 6.4 in the saline group to 
91.3 ± 3.4 in the PQ-Placebo group, P<0.001) and about 60% reduction in the placebo 
fed group (down to 143.7 ± 4.3) compared to saline injected group. The cell counts also 
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confirmed the neuroprotective effects of WS-C0Q10. Although the approximate number 
of TH-immunopositive neurons in the PQ-WS-C0Q10 group was lower than the control 
saline group, total TH-positive neuronal number was still 2.5 fold higher than in the PQ-
Water group (PO.OOl) and 1.5 fold higher than the PQ-WS-placebo group (P<0.001). 
Interestingly, the counts also revealed a higher number of TH-immunopositive neurons in 
the PQ-Placebo group in comparison to the PQ-Water group (PO.OOl), although this 
difference was not as clear in the microscopic images (Figure 3.2C). It should be noted, 
that the placebo solution contained PTS, a derivatised form of vitamin E, which could be 
responsible for the observed neuroprotection. 
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Figure 3.2 Immunohistochemical evaluation of midbrain damage. Rats were 
sacrificed, following the completion of experiment #1; brains were fixed, paraffin 
embedded and processed for immunohistochemistry. Images were captured using a Carl 
Zeiss Axiovert 200M microscope. Representative photomicrographs of midbrain sections 
showing TH-immunopositive neurons from saline injected rats (A), PQ injected water fed 
rats (B), PQ injected placebo fed rats (C) and PQ injected WS-C0Q10 fed rats (D). 
Magnification: 10X. Insets (a' to d') show the density of TH-immunopositive neurons 
and fibres in the respective groups. Magnification: 20X. The number of TH-
immunopositive neurons was counted manually (E). Data is shown as mean ± SEM. 
Statistically significant differences are indicated as: , between saline injected group and 
PQ injected water fed group, P< 0.001; m, between PQ injected water fed group and 
both PQ injected placebo fed group and PQ injected WS-CoQio fed group, P< 0.001;111114 
between PQ injected placebo fed group and PQ injected WS-CoQio fed group, P< 0.001, 
n = 3. 
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3.1.2 Biochemical Analysis 
The pro-oxidant effects of PQ such as oxidative damage to lipids and other 
cellular macromolecules, have been studied in a number of experimental systems and 
tissues other than the brain (Di Monte et al. 1986, Tamarit et al. 1998, Cheng et al. 
1999). It has been proposed that oxidative stress may initiate PQ-induced apoptotic cell 
death in cultures of cerebellar granule cells (Gonzalez-Polo et al. 2004) and may underlie 
tissue damage when PQ is directly infused into the SN of rats (Mollace et al. 2003). In 
vitro studies in our lab also indicated a number of biochemical changes induced by PQ 
treatment including oxidative stress, activation of caspases and loss of mitochondrial 
membrane potential (McCarthy et al. 2004). 
The most common tests used to analyse the damage caused by ROS include 
measuring the levels of oxidatively modified proteins, DNA and lipids. Also, the levels of 
antioxidants such as reduced form of glutathione are indicators of oxidative stress levels. 
3.1.2.1 Evaluation of Levels Oxidative Stress Markers 
3.1.2.1.1 Assessment of Reduced Glutathione after PQ Administration 
In order to assess PQ-induced oxidative damage in different regions of the brain, 
and to assess if WS-CoQio could this prevent this damage, I measured GSH content 
(Figure 3.3) in the midbrain of the rats following the three injection regime. These rats 
received 10 mg/kg of PQ once a week for three weeks. GSH is an abundant anti-oxidant, 
found in many tissues and is known to protect cells against oxidative damage (Dringen 
and Hirrlinger 2003). Depletion in GSH levels have been observed in the MPTP model of 
PD (Liang et al. 2007). 
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In my study, animals from experiment #2 were sacrificed, brain tissues were 
harvested and then dissected as well as homogenised and the DTNB assay was performed 
as described in Materials and Methods. I compared the levels of GSH in the brains of PQ-
injected groups (Placebo-fed and WS-CoQio fed groups) to the saline injected groups 
(Placebo-fed and WS-CoQio- fed groups). 
Results of GSH content analysis was expressed as percent control; the placebo-
saline group was considered the control group. In the midbrain, the GSH content in the 
PQ-Placebo group (8.11 ± 0.7) was reduced by half as compared with the saline placebo 
(16.34 ± 5.7) and saline WS-CoQio (13.19 ± 1.8) groups (PO.OOl), consistent with it 
being utilized to combat the effects of PQ in the midbrain (Figure 3.3B). However, the 
GSH level was maintained at nearly control level in the PQ-WS-CoQio group (11.05 ± 
1.1) compared with both PQ injected groups, ,P<0.001). 
A similar outcome was seen in the striatum (Figure 3.3A), where GSH levels in 
the PQ-Placebo (6.9 ± 0.69) group was reduced to half compared to the saline WS-CoQio 
(11.39 ± 1.86) group and saline placebo (15.46 ± 1.21) group. Furthermore, WS-CoQio 
offered protection against PQ-induced loss in GSH levels (10.66 ± 2.54). These results 
suggest that the anti-oxidant content of WS-CoQio formulation offset PQ effects, sparing 
the GSH system. Two way ANOVA revealed a statistical significance in the GSH levels 
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Figure 3.3 Levels of reduced GSH in the striatum and midbrain. Following the 
completion of experiment #2 rats were sacrificed and midbrain tissue was homogenized 
and assayed for GSH in the striatum (A) and midbrain (B). Data (mean ± SEM) was 
normalized to that of saline injected placebo fed group, which was taken as 100%. A) 
Statistically significant differences are indicated as: between saline injected placebo 
fed group and PQ injected placebo fed group, P< 0.001; ###, between PQ injected placebo 
fed group and saline injected WS-CoQio fed group, P< 0.001; HHH between PQ injected 
placebo fed group and PQ injected WS-CoQio fed group, P< 0.001, (n = 3). 
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3.1.2.1.2. Assessment of Levels of Lipid Peroxidation. Another marker of 
oxidative stress is lipid peroxidation. Recent studies report a higher malondialdehyde 
(MDA) level (Schmuck et al. 2002) and increased lipid peroxidation in the substantia 
nigra region of PD brains (McCormack et al. 2006). I measured the content of MDA, the 
product of lipid peroxidation, to assess the degree of PQ-induced lipid damage in the 
midbrain (Figure 3.4). There was particularly evident damage in PQ-Placebo (139.34 ± 
20.34) group as indicated by a significantly increased MDA level in comparison to 
groups injected with PQ and protected with WS-CoQio (P<0.05). Again, the MDA levels 
in PQ-WS-CoQio (93.90 ± 13.19) was nearly the same as the saline placebo (100 ± 0) and 
saline WS-CoQio (73.70 ± 23.4) groups and were significantly lower than in PQ-Placebo 
group (P<0.05). Thus, these results indicated that PQ injections lead to increased lipid 
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Figure 3.4 Levels of lipid peroxidation in the midbrain. Following experiment 2, rats 
were sacrificed; midbrain tissue was homogenized and assayed for MDA levels. Data 
(Mean ± SEM) was normalized to that of saline injected placebo fed group, which was 
taken as 100 %. Statistically significant differences are indicated as: , between saline 
injected placebo fed group and PQ injected placebo fed group, P< 0.05; * between PQ 
injected placebo fed group and saline injected WS-CoQio fed group; between PQ 
injected placebo fed group and PQ injected WS-CoQio fed group, P< 0.05 (n = 2). 
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3.1.2.2. Assessment of ATP Levels in the Striatum and Midbrain 
3.1.2.2.1 Evaluating the Levels of Mitochondrial ATP Levels after PQ 
Administration 
Studies have shown that toxins such as MPTP once accumulated in neurons, may 
cause damage by impairing mitochondrial function. As a consequence, cellular energy 
supplies in the form of ATP would be rapidly consumed, leaving cells unable to perform 
functions critical for their survival (Scotcher et ah 1990). Cell death after exposure to 
MPTP and MPP+ has been linked to ATP depletion in studies using hepatocytes and PC 
12 cells as in vitro model systems (Di Monte et ah 1986, Denton and Howard 1987, 
Singh et ah 1988). It has been shown that PQ causes mitochondrial dysfunction by 
inhibiting the electron transport chain, resulting in increased ROS production (Dinis-
Oliveira et ah 2006). In vitro studies in our lab indicated that PQ treatment caused 
depletion in ATP levels. To analyse if PQ could induce ATP depletion and accordingly, 
whether WS-CoQio could prevent ATP depletion, a luciferin-luciferase assay was 
performed using the midbrain and striatum to measure mitochondrial ATP production. 
The results were expressed as percent control where the placebo saline group was used as 
the control group. 
As shown in figure 3.5, I observed that both PQ-injected groups significantly 
decreased their ATP levels compared to that maintained by the control saline-placebo 
group in both the midbrain and striatum. In the midbrain (Figure 3.5A), the PQ-CoQio 
rats showed far less of a decline than the PQ-Placebo rats (67% vs. 52%), which missed 
significance (p=0.086). Unexpectedly, the saline-CoQio group slightly (78%) but 
significantly had reduced ATP levels. 
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Similar results were observed in the striatum region (Figure 3.5B), where the PQ-
Placebo rats showed about 30% decline in the ATP levels as compared to the saline-
placebo and the PQ-WS-C0Q10 animals. The ATP levels in the PQ-WS-C0Q10 group 
were near control (saline-placebo group). Therefore, our results indicate that WS-C0Q10 















Figure 3.5 Levels of mitochondrial ATP in the midbrain(A) and the striatum(B). 
Following experiment 2, animals were sacrificed and fresh midbrain and striatum 
homogenates were obtained. Mitochondrial fractions were separated and then subjected 
to a luciferin-luciferase assay to detect mitochondrial ATP levels. In both regions, the 
results were normalised to saline-placebo group (control group). * reveals statistical 
significance, p<0.05, (n=3). 
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3.1.2.2.2. Measurement of Total Cellular ATP Contents After PQ Exposure 
In the previous experiment, only the mitochondrial ATP was measured. However, 
these results do not reflect total ATP levels. I performed a luciferin-luciferase assay on 
the midbrain extracts to establish a steady-state content of ATP in the PQ-injected rats 
(Figure 3.6). The data revealed a nearly 50% drop in the ATP level in PQ-Water when 
compared to the saline injected group (41.4% of control, PO.OOl). The ATP levels in the 
PQ-injected animals were also lower than the saline group. The ATP levels were 
significantly higher, especially in the PQ-WS-CoQio group than in unprotected PQ-

























Figure 3.6 Levels of total cellular ATP in the midbrain. Following experiment 1, rats 
were sacrificed; midbrain tissue was homogenized and assayed for net ATP content using 
the luciferin-luciferase assay as described in Materials and Methods. Data (mean ± SEM) 
was expressed as percent of control, where Saline-Water group was used as the control 
group. Statistically significant differences are shown as: ***. between saline injected and 
PQ injected water fed group, P< 0.001; between PQ injected water fed group and PQ 
injected placebo fed group, P< 0.05; H, between PQ injected water fed group and PQ 
injected WS-CoQio fed group, P< 0.05 (n = 2). 
78 
3.1.3 Behavioural Assessments 
To determine the effects of PQ on Long Evans hooded rats and the potential 
neuroprotective effects of WS-CoQio, biochemical, histochemical as well as behavioural 
parameters were examined. Specific behavioural changes are attributed to PD, and 
analysis of these changes is fundamental when using an animal model of PD. For this 
purpose, the rats were subjected to a series of rotorod tests over the course of the three 
injection regime (experiment 2) to measure spontaneous changes in their balancing 
behaviour. These neuroprotective effects were accompanied by maintenance or even 
improved balance on the rotorod (Figure 3.7A). In fact, animals of the PQ injected WS-
C0Q10 group behaved the same on the rotorod tests as animals in both saline injected 
groups. 
3.1.3.1. Proportion of Time Spent in Walking Backwards 
Changes in the amount of time that rats in each group spent walking backward 
over the three test sessions (pre-injection, mid-injection, post-injection) are shown in 
figure 3.7A. Although all groups spent a greater proportion of their time walking forward, 
they spent 30% to 40% of their time walking backwards on their first (pre-injection) test. 
Rats in the PQ-Placebo group were the only ones that steadily reduced the amount of time 
spent spontaneously walking backward. In fact, during the post-injection test they almost 
exclusively maintained a forward walking gait. The three-way ANOVA on the 
transformed data uncovered a significant injection type among all three factors, p=0.015. 
One-way within-subjects ANOVAs for each group revealed that only rats in the PQ-
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placebo group significantly reduced their proportion of walking backwards, /?<0.01. 
There were no statistically significant effects for any changes in the other three groups. 
3.1.3.2. Vertical and Horizontal Nose Positions 
Separate analyses of rats' vertical and horizontal nose positions while on the 
rotorod did not uncover any significant changes reflecting the experimental treatments 
(i.e., PQ vs. saline injections or placebo vs. C0Q10 supplementation). As shown in figure 
3.7B, rats tended to walk forward with their noses slightly below the top of the rotorod 
(below the horizontal line at 210 pixels) and extended well away from it (177 pixels from 
the left vertical line). When rats did walk backwards, they also tended to extend their 
noses slightly below the top of and away from the rotorod. 
In summary, I found clear evidence of a motor balance dysfunction in rats that 
had suffered PQ-induced neuronal loss in the SNc (PQ-Placebo group). These rats 
drastically reduced their tendency to spontaneously turn around and walk backwards 
during and following their series of injections. On the other hand, PQ-injected rats whose 
SNc area was protected by WS-CoQio (PQ-CoQio group) retained their pre-injection 
levels of the backward gait on the final post-injection. Thus this group did not differ 
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Figure 3.7 Behavioural assessments. Rats were trained on the rotorod and behavioural 
testing was carried out. (A) Rats were placed on a moving rotorod and the time spent 
walking backwards on the rotorod was monitored. Measurements were made before (pre-
injection), during (mid-injection) and after (post-injections) the PQ-injections. The data 
points represent the mean proportion of time spent walking backwards during each 
testing session (n=6). (B) Representative image of the tracking format used for 
determining forward/backward walking posture as well as the location of nose on the 
rotorod. The horizontal line is positioned at the top of the rotorod and the two vertical 
lines determine the forward and backward walking positions. Any nose locations between 
the left and right vertical lines were not counted. 
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Thus treating animals with three injections of 10 mg/kg PQ not only induced 
neuronal loss in the SNc but also caused behavioural deficits and increased oxidative 
stress levels and decreased ATP levels in the midbrain and striatum. Interestingly, pre-
feeding with WS-C0Q10 substantially prevented loss of DA neurons, decreased oxidative 
stress and maintained and ATP levels near control. Moreover, behavioural deficits were 
also significantly reduced by WS-C0Q10 pre-feeding. 
3.2 Specificity of Paraquat Neurotoxicity and Evaluation of Neuroprotection by WS-
C0Q10 at Higher Doses of Paraquat 
This study was designed to evaluate: 
1. If higher doses of PQ could lead to a greater loss of DA neurons. 
2. Specificity of PQ-induced neuronal cell death 
3. Effects of prophylactic and therapeutic use of WS-CoQio (pre- and post- injection 
feeding) on neuroprotection 
4. Effects of age on PQ-induced toxicity 
I wanted to evaluate the effects of higher doses of PQ and examine if a higher 
dose would cause increased death of DA neurons. While trying to improve the existing 
model, I came across the advantages of using multiple insults to cause death of DA 
neurons, in the literature. Reportedly, eight injections of 10 mg/kg PQ alone or 10 mg/kg 
PQ in combination with another fungicide, maneb (30 mg/kg) were used to induce death 
of DA neurons (Thiruchelvam et al. 2000a, Thiruchelvam et al. 2000b, Cicchetti et al. 
2005, Saint-Pierre et al. 2006). Therefore I began a study involving a combination of 10 
82 
mg/kg PQ and 30 mg/kg maneb injected twice a week for four weeks. This combination 
proved to be fatal to a number of rats and was therefore discontinued. I decided use eight 
injections of 10 mg/kg PQ alone (twice a week for four weeks) and analyze if more 
neuronal damage could occur with this regime than with only three injections. However, 
this regime also proved to be fatal Long Evans hooded rats. 
Since the eight injection PQ regime was highly toxic to the rats, I decided to use 
five injections of 10 mg/kg PQ, and evaluate if this regime could increase the loss of DA 
neurons compared to three injections. The five injection PQ regime did not cause any 
fatalities. Therefore preliminary studies were carried out to evaluate the nigral loss and 
biochemical parameters. 
3.2.1 Evaluating the Effects of the Five Injections of PQ and the Efficacy of 
WS-CoQio as a Prophylactic and Therapeutic Agent on Nigral Cells 
Our studies with three injections of PQ clearly revealed the neuroprotective effect of 
WS-CoQio as a prophylactic agent. However, the ability of this compound as a 
therapeutic agent needed to be studied. To study the effects of WS-CoQio as a 
prophylactic agent, WS-CoQio feeding was started before the commencement of PQ 
injections; to investigate the therapeutic abilities of WS-CoQio, WS-CoQio feeding began 
only after the last injection. For comparison, the DA neuronal numbers were counted 
using TH-immunostaining. 
The number of DA neurons was estimated by counting TH-immunopositive 
neurons in the substantia nigra pars compacta. Assessment of midbrain sections showed a 
clear decrease in the density of TH-immunopositive neurons in rats injected five times 
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with 10 mg/kg PQ. In this preliminary study, I compared the prophylactic effects of WS-
C0Q10 (pre-fed) to its therapeutic effects (post-fed). As shown in figure 3.8(A-B) rats 
belonging to the PQ-Water group were vulnerable to PQ, as it caused about 30% 
reduction of TH-positive neurons compared to the saline injected groups. Rats belonging 
to the PQ-Placebo pre-fed group showed a decline of about 26%, while rats of the PQ-
CoQio pre-fed group showed only about 14% loss in the number of TH-positive neurons, 
compared to the control group. When WS-CoQio is fed after PQ injections, it still offered 
neuroprotection against PQ toxicity and prevented further loss of DA neurons (28% 
decline in TH-immunopositive cells in PQ-CoQio post-fed rats compared to about 40% 
decline in PQ-Placebo post-fed rats) as indicated in figure 3.8A-B. 
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Figure 3.8 Evaluation of neuroprotective effects of WS-CoQio as a prophylactic and 
therapeutic agent. (A) Pictures of TH-immunostained sections were obtained by using a 
Nikon ECLIPSE E800 microscope. Original magnification 10X. (B) TH-positive neurons 
were counted manually in the substantia nigra pars compacta of rats treated with five 
injections of 10 mg/kg PQ. Data is represented as percentage of control. Mean ±SEM, n = 
2. 
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3.2.2 Assessment of Oxidative Stress Levels 
3.2.2.1 Evaluating Levels of Reduced Glutathione after PQ Treatment 
As mentioned earlier, GSH is a very important anti-oxidant in the brain. In this 
study, the GSH content was measured from the midbrain. The results were 
normalised to the Saline-Water (control) group. The effects of prophylactic versus 
therapeutic applications of WS-C0Q10 on levels of GSH after PQ treatment were 
analysed. There was a loss of about 40% in GSH content in the PQ-Water group as 
compared to the Saline-Water (control) group (Figure 3.9). Although the PQ-Placebo 
pre-fed group showed higher GSH levels than PQ-Water group, the GSH levels were 
maintained at a near control level in the PQ-WS-CoQio pre-fed group. Interestingly, 
the amount of GSH in the PQ-CoQio post-fed group was maintained at a slightly 
higher level as compared to PQ-Water and PQ-Placebo post-fed groups. 
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Figure 3.9 Evaluating levels of reduced GSH in the midbrain. After the completion of 
the experiment, rats were sacrificed, midbrain tissue was homogenized and assayed for 
GSH Data (Mean ± SEM) was normalized to that of Saline-Water group, which was 
taken as 100 %. n = 2. 
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3.2.2.2 Evaluating the Levels of Lipid Peroxidation in the Midbrain 
As mentioned earlier, levels of oxidative stress can be monitored by evaluating 
the levels of lipid peroxidation. I measured the content of MDA, the product of lipid 
peroxidation, to assess the degree of PQ-induced lipid damage in the midbrain. The 
results were normalised to the Saline-Water or the control group. The effects of 
prophylactic versus therapeutic applications of WS-C0Q10 on levels of lipid peroxidation 
after PQ treatment were analysed. There was an increase of about 34% in lipid 
peroxidation levels in the PQ-Water group as compared to the Saline-Water group 
(Figure 3.10). Although the PQ-Placebo pre-fed group showed lower lipid peroxidation 
levels than PQ-Water group, the lipid peroxidation levels were maintained at a slightly 
lower level in the PQ-WS-CoQio pre-fed group. Furthermore, the lipid peroxidation 
levels in the PQ-WS-CoQio post-fed group were maintained at a near control level as 
compared to PQ-Water and PQ-Placebo post-fed groups. Thus WS-CoQio does offer 






Figure 3.10 Evaluating the levels of lipid peroxidation in the midbrain. After the 
completion of experiment, rats were sacrificed, midbrain tissue was homogenized and 
assayed for lipid peroxidation. Data (Mean ± SEM) was normalized to that of Saline-
Water group, which was taken as 100 %. n = 2. 
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3.2.3 Analyzing the Levels of Total ATP in the Midbrain 
The net cellular ATP content, however, reflects a balance between energy production 
and consumption, in which an increase would be expected under oxidative stress 
conditions since ROS detoxifying enzymes are energy dependent. I performed a luciferin-
luciferase assay on the midbrain extracts to establish a steady-state content of ATP in the 
PQ-injected rats (Figure 3.11). The results were normalised to the saline-water or the 
control group. The effects of prophylactic versus therapeutic applications of WS-C0Q10 
on levels of total ATP after PQ treatment were analysed. The data revealed a 44% loss in 
the ATP levels in PQ-Water group when compared to the Saline-Water group. The ATP 
levels in the all the PQ-injected rats were also lower than the Saline-Water (control) 
group. Although the PQ-Placebo pre-fed group showed higher ATP levels than PQ-Water 
group, the ATP levels were maintained even higher in the PQ-WS-CoQio pre-fed group. 
Interestingly, the amount of ATP in the PQ-CoQio post fed was maintained at a slightly 






Figure 3.11 Evaluating the levels of total ATP in the midbrain. After the completion 
of experiment, rats were sacrificed, midbrain tissue was homogenized and assayed for 
ATP levels using luciferin-luciferase method. Data (Mean ± SEM) was normalized to that 
of Saline-Water group, which was taken as 100 %. n = 2. 
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3.2.4 Evaluating the Effect of PQ on Protein Expression. Western blot analysis 
was performed on the midbrain homogenates to evaluate PQ induced response on the 
level of proteins such as tyrosine hydroxylase, parkin, a-synuclein and GFAP. As 
mentioned earlier, TH is a marker for DA neurons. Preliminary results indicate a decrease 
in the levels of TH in all the rats subjected to PQ treatment as compared to their saline 
injected counterparts, correlating to the loss of DA neurons, a-synuclein expression is 
increased in midbrains of rats challenged by PQ (Bove et al. 2005). Up regulation of this 
protein has been observed in MPTP-treated squirrel monkeys (McCormack et al. 2008). 
Our preliminary results indicate no change in the expression levels of a-synuclein post 
PQ injections. Parkin may be critical for protecting DA neurons from toxic insults by 
targeting misfolded or oxidatively damaged proteins for proteasomal degradation (Perez 
et al. 2005). When I examined parkin levels, they remained unchanged between saline 
and PQ-injected rats (Figure 3.12). These are preliminary results and no conclusions can 
be drawn from this data. 
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Figure 3.12 Evaluating the levels of protein expression. Western blots of TH, parkin, 
a-synuclein and GFAP proteins in the midbrain of rats treated with 10 mg/kg PQ once a 
week for five weeks. Midbrain homogenates were subjected to western blot analysis for 
analyzing the expression levels of different proteins. Ponceau S staining was performed 
to confirm equal loading in all wells. 
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3.2.5 PQ-induced Selective Damage of DA Neurons in the SNc 
3.2.5.1 Selectivity of PQ-induced Neuronal Loss 
Results have indicated a loss in DA neurons after PQ injections. The selectivity 
of PQ toxicity was further evaluated by immunohistochemical examination of neurons in 
the hippocampus region, cortex and the cerebellum. I stained the sections (coronal 
sections across the substantia nigra region) with anti-NeuN, as well as hematoxylin and 
eosin (H&E). 
H&E staining has been widely used to label viable and damaged cells in the brain 
(Schmued et al. 1997). Hematoxylin stains nuclei blue and eosin stains cytoplasm pink. 
NeuN is a neuronal-specific protein (Mullen et al. 1992) that is frequently used as a 
specific marker for viable and intact neurons (Mullen et al. 1992, Xu et al. 2002, Hassen 
et al. 2004). Immunohistochemistry of NeuN shows that this protein is visible both in 
nuclei and in portions of the cytoplasm of neurons, such as the cell body, axons and 
dendrite processes (Mullen et al. 1992). 
Neurons in the hippocampus are vulnerable to a variety of toxins 
(Stoltenburgdidinger 1994, McCormack et al. 2002) and therefore were identified as a 
cell population that could be a potential, albeit non-intended target of PQ toxicity. NeuN 
staining of the hippocampus region in the saline and PQ-injected rats did not reveal any 
significant decrease in the numbers of neurons as shown in figure 3.13 A. A similar result 
was observed for NeuN staining of the cortex (Figure 3.13B). However, a decrease in the 
number of NeuN positive cells was observed in the midbrain region of rats treated with 
PQ. Moreover, H& E staining of saline and PQ treated rats did not reveal any damage to 
cells in the hippocampus region and cerebellum. The gross morphology of the midbrain 
also did not seem to be affected by PQ treatment (Figure 3.13D). These studies were 
performed by a neurologist (Dr. T.S. Sridhar) who interpreted the results (in a blind 
study). These results need to be quantified and also confirmed. 
Saline water Paraquat water 
Saline-Water 




Saline water PQ water 
Hippocampus 
region 
Saline water PQ water 
Midbrain 
Saline-Water PQ-Water 
Figure 3.13 Effects of PQ on neuronal cells in different areas of the brain. Coronal 
brain sections were immuno-stained for NeuN as well as stained with Hemtoxylin and 
Eosin (H&E). Pictures were obtained using a Leica DM IRB microscope. NeuN immuno-
staining in hippocampus region (A), the cortex (B) and the midbrain region (C). H&E 
staining of the hippocampus, midbrain and cerebellum (D). Pictures were taken at 40 X 
magnification. 
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3.2.5.2 PQ Treatment does not Cause any Damage to Peripheral Tissue 
Most of the rats treated with PQ gained weight progressively, albeit a little slower 
as compared to their saline counterparts especially during the weeks of injections. No 
significant weight loss was observed between the saline and PQ-treated rats (Figure 
3.14). More importantly, there were no fatalities after five PQ injections. 


















Figure 3.14 Weights of rats for the five injection PQ regime. Weights were recorded 
for each animal every week. An average weight of the four animals in a cage is shown 
here (n=4). 
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Since the herbicide was injected intraperitoneally, a general pathological analysis 
of the liver, kidneys and lungs was carried out. The liver and kidneys are responsible for 
elimination of toxins from the body. H&E stained sections of these tissues were evaluated 
by a pathologist (Dr. Jyothi S. Prabhu) in a blind study, without the knowledge of 
treatment groups. Results revealed that there was no damage to the liver or kidneys 
(Figure 3.15). Acute PQ exposure has been shown to cause severe damage to the lungs 
(Dinis-Oliveira et al. 2006). The analysis of the lung tissue revealed that there was blood 
present in the tissue making it difficult to draw any conclusions. The arrows indicate the 
presence of blood cells. 
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Figure 3.15 Analysis of peripheral organs after PQ exposure. The lungs, liver and 
kidneys were fixed and 8 p. sections were obtained from different parts of the organs and 
stained with H&E. The pictures of the lungs and liver were taken at 40X magnification 
while the pictures of the kidney were taken at 63X magnification. 
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3.2.6 PQ Induces Astroglia Response in the Midbrain 
Several studies have documented that glial activation and neuroinflammatory 
processes play an important role in the pathogenesis of PD (Hirsch et al. et al. 2005, 
Wersinger and Sidhu 2006, Rogers 2008). Glial fibrillary acidic protein (GFAP), which is 
abundantly expressed by astrocytes in the central nervous system (CNS), is widely used 
as a marker of astrocytic activation (Eng et al. 2000). It has shown in mice that PQ 
exposure does lead to inflammation (McCormack et al. 2002). To evaluate the effects of 
PQ on inflammation in Long Evans Hooded rats, I immunostained midbrain sections for 
GFAP. In order to do so, rats were injected with 10 mg/kg PQ (once a week for five 
weeks), sacrificed and perfused. The brains were fixed in 10% buffered formaldehyde, 
sectioned and stained with anti-GFAP antibody as in Materials and Methods. The 
staining revealed increased astrocyte expression of GFAP in all PQ-injected groups 
(Figure 3.16B-D) when compared to the saline-injected rats (Figure 3.16A).The strongest 
GFAP response, however, was seen in the brains of the rats that drank the WS-CoQio 
supplemented water. Under a higher magnification, the astrocyte processes appeared to 
be thicker and fibrous (hypertrophic), typical of reactive astrocytes, which were rarely 
seen in the saline-injected rats receiving regular drinking water (Figure 3.16 b' c' d' as 
compared to a'). The quantitative cell counts confirmed the increased presence of reactive 
astrocytes in the PQ-injected groups, but especially in the WS-CoQio groups (Figure 
3.16E). The number of counted astrocytes in the WS-CoQio groups was nearly double 
that in the saline group and even the PQ-Placebo fed and PQ-WS-CoQio fed groups. The 
astrocytic presence in the later two groups was also significantly higher than in the 
control group (Saline-Water). Thus, the neuroprotective effects of WS-CoQio were 
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clearly associated with the significantly induced astroglia response (PQ-WS-CoQio fed 
group vs. saline injected group, PO.OOl; PQ-WS-CoQio fed group vs. PQ-Placebo fed 
group, PO.OOl). 
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Figure 3.16 Midbrain astroglia responses. Brains from rats were fixed, paraffin 
embedded and processed for immimohistochemistry. Representative photomicrographs of 
midbrain sections showing GFAP-immunopositive astrocytes from saline-injected group 
(A), Saline-injected Water-fed group (B), PQ-injected Water-fed group (C) PQ-injected 
Placebo-fed group and (D) PQ-injected WS-CoQio-fed group. Magnification: 20X. Insets 
(a' to d') show a single cell at higher magnification from the respective groups. (E) The 
number of astrocytes with increased GFAP expression was scored; at least 300-500 cells 
were counted at 40X magnification in 2 separate experiments. The number of astrocytes 
in control (Saline-Water group) was taken as 100% and the treated groups were expressed 
as percentage of control. Statistically significant differences are indicated as: between 
saline-injected group and PQ-injected Water-fed group, P< 0.001; ###, between PQ 
injected Water-fed group and both PQ-injected Placebo-fed group and PQ injected WS-
CoQio fed group, P< 0.001;HHH, between PQ-injected Placebo-fed group and PQ-injected 
WS-CoQio-fed group, P< 0.001, (n=2). 
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Furthermore, I observed astrocyte activation in the brain upon PQ treatment, 
especially in the hippocampus region. Preliminary results revealed that increased 
numbers of activated astrocytes were seen in the PQ-injected rats as compared to the 
saline-injected rats (Figure 3.17A). Interestingly, I observed that the orientation of 
astrocytes found above the hippocampus was unique in both the saline and PQ injected 
rats and there was more activation of these cells after PQ treatment (Figure 3.17B). 
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Figure 3.17 Astroglia responses in other brain areas. Brains from rats were fixed, 
paraffin embedded and processed for immunohistochemistry as described in the Materials 
and Methods. Representative immunofluorescence images of GFAP-immunoreactive 
astrocytes from hippocampus region (A), and above the hippocampus region (B) of rats at 
40X magnification on a Leica DM IRB microscope. (n=l) 
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3.2.6.1 Evaluating the Levels of Different Chemokines and Cytokines after 
PQ Administration 
Cytokines and chemokines are extracellular signaling molecules that mediate 
communication between cells. They are released from cells and play pivotal roles in 
many biological processes such as cellular growth, differentiation, migration, gene 
expression, immunity and inflammation (Borish and Steinke 2003). I observed activation 
of astroglia in the midbrain and hippocampus after PQ exposure. Since the main 
communication signals used by microglia are cytokines and chemokines (Rock and 
Peterson 2006) I then measured the levels of various cytokines, using a cytokine array kit. 
This assay allowed us to determine the levels of multiple cytokines in a single experiment 
and to understand if the cytokines being over expressed are neuroprotective, or if they 
mediate neurotoxicity. Results showed that after injections with PQ, the CNTF, 
Fractalkine or CX3CL1, sICAM or CD54, LEX, L-Selectin or CD62L / LECAM-1 and 
Thymus cytokine or CXCL-7 are over expressed. In the PQ-CoQio group, there was over 
expression of the cytokine L-Selectin or CD62L / LECAM-1 indicated by the red circle 
(Figure 3.18). Our results are preliminary and need to be confirmed by further 
experiments. 
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Positive controls Al,2, A19,20 andDl,2 
CNTF A9,10 
Fractalkine or CX3CL1 All,12 
sICAM or CD54 A15.16 
LIX C 9, 10 
L-Selectin or CD62L / LECAM-1 CI 1,12 
Negative controls D19,20 
Thymus cytokine or CXCL-7 D5,6 
Figure 3.18 Evaluating the levels of cytokines/chemokines. The midbrain homogenates 
from saline and PQ- injected rats were subjected to a cytokine array. The results show the 
expression profiles of different cytokines/chemokines. 
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3.2.7 Effects of Age on PQ-Induced Toxicity 
3.2.7.1 Effect of PQ on Nigral Cells 
Microscopic assessment of midbrain sections stained with an antibody against 
TH showed a clear decrease in the density of TH-positive neurons after the last of the five 
10 mg/kg PQ injections. The number of DA neurons was estimated by counting TH-
immunopositive cells in the SNc manually. In this preliminary study, I compared the 
effects of PQ on old rats. The data were normalised to the Saline-Water group which was 
considered the control group. As shown in figure 3.19(A-B), rats belonging to the PQ-
Water group were vulnerable to PQ which caused about 50% reduction of TH-positive 
neurons when compared to the saline injected counterparts. Rats belonging to the PQ-
Placebo showed a decline of about 35%, while those belonging to the PQ-CoQio group 
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Figure 3.19 Effects of PQ on nigral cells in old rats. (A) Pictures of TH-immuno-
stained sections from old rats using the Leica DM IRB microscope. Original 
magnification 10X. (B) TH-positive neurons were counted manually in the SNc of rats 
treated with five injections of 10 mg/kg PQ. The data (Mean ±SEM) were normalised to 
the Saline-Water group which was considered as the control group (n=l). 
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3.2.7.2 Biochemical Analysis 
3.2.7.2.1 Analysis of GSH Levels 
In this study, GSH content was measured from the midbrain. The effect of PQ on 
levels of GSH in old and young rats was analysed. In the young rats, a loss of about 40% 
in GSH content in the PQ-Water group as compared to the Saline-Water (control) group 
was observed (Figure 3.20). In the PQ-CoQio group, higher levels of GSH were observed. 
However, in the case of the old rats, the saline-injected rat had a lower level of GSH as 
compared to the young counterparts. There was a loss of about 60% GSH content in the 
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Figure 3.20 Evaluating GSH levels in old and young rats. Rats were sacrificed and 
midbrain homogenates were subjected to GSH assay. Data (mean ±SEM) is represented 
as percentage of control, n =2. 
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3.3 Evaluation of the Probable Mechanism of C0Q10 Neuroprotection 
A portion of this study to evaluate the mechanism of neuroprotection by WS-
CoQlO was done with Dr. Jafar Naderi. 
Studies in our lab have shown that WS-C0Q10 can prevent HEK 293 cells 
from undergoing apoptosis when exposed to hydrogen peroxide-induced oxidative stress 
(Naderi et al. 2006). H^C^-induced mitochondrial membrane collapse and increased ROS 
generation is involved in apoptosis (Naderi et al. 2006). Studies in our lab have shown 
that oxidative stress induced by either H2O2 or paraquat (PQ) leads to mitochondrial 
dysfunction and loss of mitochondrial membrane potential (Somayajulu et al. 2005, 
McCarthy et al. 2004). Our studies have also indicated that pre-treatment with WS-C0Q10 
prevents the loss of mitochondrial membrane potential (Somayajulu et al. 2005, 
McCarthy et al. 2004). 
C0Q10 (ubiquinone) is found in inner mitochondrial membrane where it shuttles 
electrons from complex-I and I to complex-Ill. I wanted to investigate if protection by 
WS-C0Q10 is based on its ability to act as an anti-oxidant, or if this compound is capable 
of stabilizing mitochondria under oxidative stress. 
In order to examine the role of WS-C0Q10 as an anti-oxidant as well as a stabilizer 
of the mitochondria, I used compounds such as complex-I blockers and Bax protein, 
which are known to cause damage to mitochondria and then observe the effects of this 
formulation. 
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3.3.1 WS-CoQio Prevents Mitochondrial ROS Production Induced by Complex-I 
Blockers Such as Rotenone and Paraquat 
Mitochondrial dysfunction has been associated with increased production of 
reactive oxygen species (ROS) (Li et al. 2003). Several studies have shown that 
complex-I inhibitors such as rotenone can induce mitochondrial ROS production (Sousa 
et al. 2003). I was interested in studying the protective effects of WS-CoQio against 
oxidative stress induced mitochondrial damage. In order to study the effects of WS-
CoQio, isolated mitochondria were pre-treated with WS-CoQio for 20 min and then 
treated with 10 fiM rotenone. ROS production was measured using a horseradish 
peroxidase-based PHPA oxidation method. This method is used to detect H2O2 that is 
produced from intact mitochondria when they are incubated with different mitochondrial 
chain substrates and inhibitors. 
Results from this study indicate that rotenone-treated mitochondria isolated from 
SH-SY5Y cells show a significant increase in the production (p<0.05) of ROS as 
compared to control (Figure 3.21A). The mitochondria pre-treated with WS-C0Q10 and 
exposed to rotenone showed a significantly lower ROS production compared to those 
treated with rotenone alone (p<0.05). Therefore WS-C0Q10 functions at the mitochondrial 
level and inhibits mitochondrial ROS production induced by rotenone. 
A similar study using PQ was also performed. Our results clearly indicated there 
was an increase in mitochondrial ROS production upon PQ treatment. A significant 
reduction (p<0.05) in ROS production was observed in mitochondria pre-treated with 
WS-C0Q10 and exposed to rotenone (Figure 3.21B). In conclusion, WS-C0Q10 reduces 
mitochondrial ROS production induced by complex I inhibitors. 
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Figure 3.21 Evaluating ROS production in isolated mitochondria. SH-SY5Y cells 
were grown, lysed,mitochondria was isolated and treated with either 10 ^M Rotenone 
(A) and 200 |liM PQ (B) in the presence and absence of WS-CoQio- ROS production was 
measured using PHPA as described in the Materials and Methods. Statistical significance 
is denoted by *, p<0.05. 
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3.3.2 WS-CoQio Inhibits ROS Generation Induced by Bax in Isolated Mitochondria 
Bax is a pro-apoptotic protein of the Bcl-2 family of proteins that translocates to 
the mitochondria during apoptosis, inducing release of mitochondrial components such as 
cytochrome c and apoptosis inducing factor (AIF), which activate downstream events that 
culminate as apoptosis. Previous studies in our lab have shown that incubating Bax with 
isolated mitochondria leads to the production of reactive oxygen species (ROS) and 
release of cytochrome c (Gueorguieva et al. 2006). In this study I evaluated the 
neuroprotective effects of WS-CoQio on Bax-induced mitochondrial damage. Isolated 
mitochondria from normal HEK293 cells were treated with purified Bax protein to 
compare the protection offered by WS-CoQio. Our results indicate that ROS production 
from isolated mitochondria was increased in the presence of Bax, implying that indeed 
Bax causes mitochondrial dysfunction; however, mitochondria pre-treated with WS-
C0Q10 had significantly inhibited ROS production (Figure 3.22). These results clearly 
indicate that WS-CoQio is capable of directly inhibiting Bax-induced mitochondrial 
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Figure 3.22 Evaluating ROS generation in mitochondria isolated from HEK 293 
cells treated with Bax in the presence or absence of WS-CoQio. Isolated mitochondria 
from 293 cells were incubated with Bax in the presence and absence of WS-CoQio and 




In this study, I have successfully induced DA neuronal loss specific to the SNc in 
Long Evan's hooded rats by administering PQ. Studies have revealed that PQ induces 
oxidative stress, mitochondrial dysfunction as well as astrocyte activation. More 
importantly, I observed neuroprotection by WS-C0Q10 against PQ-mediated toxicity. This 
formulation not only prevented neuronal loss but also offered protection against oxidative 
stress and mitochondrial dysfunction both as a prophylactic and therapeutic agent. 
Interestingly, I also observed protection against mitochondrial damage induced by 
rotenone, PQ and Bax in in vitro studies. 
4.1 Animal Models used for Studying PD 
In order to better understand the pathogenesis, and develop neuroprotective 
strategies, a good and reliable model of PD is pivotal. Until recently, very little was 
known about how and why neurodegeneration ensues and progresses in PD. Much of 
information regarding the etiology and pathogenesis of PD is obtained from clinical 
studies, post-mortem studies, and epidemiological studies. Accessibility to a human brain 
is limited because of ethical approval, availability of postmortem brain tissue, and 
difficulty in drawing definitive conclusions due to individual variability and differences 
in tissue quality (Emborg 2004). The main characteristic of a PD model should be the 
loss in DA neurons in the SNc. Although in vitro studies have proved to be a tool in 
deciphering many mechanisms, cell culture systems cannot closely replicate the complex 
environment in the human brain. Animal models can help to bridge this gap. Compared to 
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cell culture studies, animal models can evaluate the degree of impairment in motor 
function observed in PD (Emborg 2004). Rodents are a common choice of animals used 
to study PD. Rats have been the model choice to study several human diseases. In the 
context of neurological sciences, they have proved to be an important tool to study 
processes like neural development, diseases, neurodegeneration, addiction and behavior. 
There are many advantages of using rats: (1) availability of extensive baseline data for a 
meaningful interpretation of experimental data, (2) larger size makes live operations 
feasible and (3) certain physiological similarities of rats to humans (Conn 2007). 
Recent studies suggest that PD may arise from a combination of genetic 
susceptibility and exposure to environmental toxins (McCormack et al. 2002, Di Monte 
2003, Dinis-Oliveira et al. 2006). Indeed, several environmental risk factors such as 
metals and herbicides have been linked to the incidence and progression of PD (Dinis-
Oliveira et al. 2006). Amongst these factors, the herbicide paraquat (PQ) shows a clear 
neurotoxicity in the CNS. PQ was chosen as the toxin to induce Parkinsonism in our 
studies because PQ is an environmental toxin and also its chemical structure is similar to 
that of MPP+ (Figure 6). Moreover, there is strong evidence of correlation between long 
term PQ exposure and increased risk of PD (Uversky 2004). PQ can enter the CNS 
through neutral amino acid transporters associated with the blood brain barrier system 
(McCormack et al. 2002) and into dopaminergic neurons via DAT (Ossowska et al. 
2005a) and damages the SNc neurons in mouse models (McCormack and Di 
Monte2003). It has also been reported that a prolonged exposure to non-pneumotoxic 
levels of PQ causes the damage to basal ganglia (Dinis-Oliveira et al. 2006). 
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4.2 Challenges Associated in Finding a Neuroprotective Therapy for PD 
There is no perfect model of PD to test strategies for neuroprotection, yet the 
models in existence do portray the basic characteristics required. Specific requirements 
need to be met by an animal model of PD in order to enable the testing of neuroprotective 
strategies. These include: (1) induction a replicable nigral lesion; (2) the loss of DA 
neurons should occur stably over time without any spontaneous recovery and (3) there 
should be a window of opportunity in order to design a neuroprotective strategy. A 
successful neuroprotective agent should be able to offer protection from behavioural 
impairment, pathological degeneration and neurochemical deficits (Emborg 2004). 
4.2.1 Limitations of Current Models used for Neuroprotection 
Cell culture systems are very essential tools to screen compounds. Most putative 
neuroprotective drugs are tested first on cultured neurons to determine whether they can 
protect cells from a variety of toxins. However, cell culture models do not provide insight 
into how a drug will behave in a complex organism. In order to evaluate the capacity of a 
drug to protect DA neurons from toxic insults, its side effects and treatment-associated 
complications, in vivo models are indispensable. 
4.2.1.1 Drawbacks of Animal Models used to Study PD 
PD a complex disease occurs primarily in the SNc but degenerative changes also 
occur in the central and peripheral nervous system (Lang 2004a). Several models 
currently in use, exhibit the characteristic features of PD, but none of them closely mimic 
the complex features of human PD. 
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Rodent models (mice, rats) are advantageous because they are easily accessible , 
their reproduction rates are high and are they are easy to house (only a small living 
space, simple feeding and drinking schedules is needed) (Emborg 2004). A varied 
susceptibility exists between species as to how they respond to neurotoxins. For example, 
mice are more susceptible to MPTP than rats. Besides this, different strains of mice and 
some even within a given strain exhibit different sensitivity to MPTP (Sedelis et al. 
2003). Furthermore, age, gender and body weight also play an important role in 
determining the sensitivity of an animal to neurotoxins (Przedborski and Vila 2001). 
Similar observations have been made in terms of rats. For example, Lewis rats require 
two fold higher dosing of 6-OHDA than Fischer or Sprague-Dawley rats. Interestingly, 
when rotenone is administered in Lewis rats, there is less variability and more 
consistency compared to Sprague-Dawley rats (Betarbet et al. 2002). Evidence of 
neuroprotection in rodents does not guarantee similar results in non-human primate 
models, given the larger volume and complexity of a monkey brain. However, translation 
to human subjects may prove to be even more intricate (Emborg 2004). The advantage of 
using an animal model is to obtain a phylogenetic perspective about the odds of success 
when translating a therapy to humans. In summary, due to the several advantages of 
utilizing animal models, they have been developed to test neuroprotective strategies in 
neurodegenerative disorders. However, these models are ongoing efforts of improvising 
and improving existing techniques to evaluate neuroprotective compounds. 
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4.2.1.2 The Precise Causative Factors of PD are Unknown 
One of the biggest challenges in developing neuroprotective strategies is that the 
exact causative factors of PD remain elusive. While some familial cases of PD are linked 
with a particular gene mutation, most cases occur sporadically and are idiopathic. If the 
precise mechanisms underlying cell death in PD could be determined, this may allow the 
identification of probable targets for the development of putative neuroprotective agents 
(Olanow et al. 2008). Current drugs have focused on blocking oxidative stress, 
excitotoxicity, mitochondrial dysfunction, and signaling pathways that might be 
connected with apoptosis. Nonetheless, it remains vague which, if any, of the proposed 
pathogenic mechanisms that have been implicated in PD is primary and initiates the 
apoptotic program. It is possible that neuronal cell death in PD occurs as a consequence 
of an overlap of multiple pathogenic factors that interact in a complex network, 
contributing to neuronal cell death in different individuals. Interestingly, studies have 
shown that patients carrying the same gene mutation, and who are family members may 
exhibit different clinical symptoms and different pathology (Olanow et al. 2008). This 
theory would imply that a combination of various (neuroprotective) agents acting 
simultaneously on different mechanisms might be required in order to achieve 
neuroprotection. 
4.3 PQ-induced Loss of DA Neurons and Dopamine Deficiency in the Striatum 
Since the dopaminergic neurons are densely packed in the SNc, loss of these 
neurons can be measured by histochemical methods. I have immunostained for TH 
because this enzyme is often used as a phenotypical marker to determine neuronal loss. 
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The rate of dopaminergic neuronal loss in the SNc may be accelerated by local factors to 
which these neurons may be uniquely vulnerable. These factors include free radical 
formation, reduced protection from oxidative stress, high levels of DAT, increased iron 
concentrations, increased glutamate input and neuromelanin formation (Lang 2004b). 
Our data clearly confirmed the toxicity of systemically administered PQ, 
especially towards DA neurons of the SNc. Thus, in the first phase of this study, this 
herbicide effectively killed approximately 65% DA neurons in adult male Long-Evans 
hooded rats and induced PD-like symptoms (Figure 3.2). Similar results have been shown 
by (Brooks et al. 1999). They used C57BL/6J strain of mice and used 3 injections of 10 
mg/kg paraquat. Their study revealed significant losses of TH positive neurons in the 
substantia nigra pars compacta (-61% loss) and their terminals in the striatum (-90% 
loss) after treatment with paraquat at the same dosage of the neurotoxin used in our study. 
Furthermore, low dose PQ-treated mice (5 mg/kg) showed a 36% loss of dopaminergic 
cells (Brooks et al. 1999). 
Furthermore, in the second phase of this study, our preliminary results with older 
animals showed a loss of about 50% neurons in the substantia nigra pars compacta 
(Figure 3.19). This is certainly higher than the 35% loss seen in younger animals (Figure 
22). A loss in TH expression levels was clearly observed in all the animals treated with 
PQ when compared to saline injected counterparts (Figure 3.12). Older animals, like 
humans, develop age-related changes in the nigrostriatal system, which resemble the 
early stages of nigrostraital degeneration. The extents of these changes vary from species 
to species (Emborg 2004). McCormack et al. showed a loss of about 25% in the 
dopaminergic neuronal numbers in C57BL/6 mice which were exposed to 10 mg/kg 
paraquat for three weeks (McCormack et al. 2002). Furthermore, their study revealed an 
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increased loss of dopaminergic neurons in the SNc of older animals when compared to 
their younger counterparts following PQ injections. Eighteen month-old animals exposed 
to PQ lost about 35% DA neurons, while five month-old animals showed a loss of about 
25% dopaminergic neurons. Similar results have been obtained from paraquat maneb 
(PQ/MB) studies in rats (Sprague-Dawleys), where the authors have revealed that older 
animals are more susceptible to brain toxicity from PQ/MB exposure (Thiruchelvam et 
al. 2003, Saint-Pierre et al. 2006). However, there exists a lot of discrepancy in data 
regarding the effects of age on paraquat toxicity. A recent study in mice has shown that 
paraquat toxicity is age independent and demonstrated that young animals are as 
susceptible as old rats to this particular neurotoxin (Peng et al. 2007). Studies with six to 
eight rats (per group) will be needed to establish statistical significance and confirm 
preliminary results. 
Given the fact that there is variability in the way animals respond to paraquat 
treatment, discrepancy in our data is not surprising. There are conflicting reports about 
the effects of paraquat following systemic exposure in mice (Bove et al. 2005). Also 
there is a strong indication of the variability in the response to toxins within different 
species of rats (Emborg 2004). Studies with rotenone have indicated that there is 
variability within a batch of animals as to how they respond to rotenone treatment. It has 
been reported that while some animals were sensitive to rotenone treatment, others did 
not respond to treatment at all (Betarbet et al. 2002). 
I noticed that eight injections of 10 mg/kg PQ alone and 10 mg/kg PQ along with 
30 mg/kg maneb (Thiruchelvam et al. 2002) proved to be fatal for Long Evans hooded 
rats. Animals treated with eight injections of lOmg/kg paraquat alone (twice a week for 
four weeks) regime in our lab suffered fatalities before completion of eight injections. 
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However, in the first batch, 3 animals (1 from PQ-Water, 1 from Saline-CoQio, 1 from 
PQ-Placebo) did not complete the injection regime and died halfway. Therefore I fixed 2 
animals from each group in formaldehyde and froze 1 animal from each group to perform 
biochemical analysis. In the second batch, 8 animals (4 from PQ-Placebo, 3 PQ-CoQio, 1 
from saline- water) did not complete the treatment and died about halfway through the 
treatment. I fixed all the animals with 10% buffered formaldehyde and used them for 
histochemistry. There were no drastic reductions in weights between the saline and PQ 
injected animals (data not shown). Since we did not have statistically sufficient animals, 
this study was used for standardising the protocols for immunohistochemistry. However, 
this dose seems to be well tolerated by Sprague Dawley rats and C57BL/6 mice 
(Thiruchelvam et al. 2000a,b, Cicchetti et al. 2005). This indicates that Long Evan's 
hooded rats may be more sensitive to toxins. 
Assessment of catecholamine contents in the nigrostriatal system provides a 
profile of the production as well as metabolism of dopamine. Previous reports have 
indicated that systemic administration of PQ significantly decreased the level of DA and 
its metabolites in the striatum. PQ decreased DA level by 20%, DOPAC and HVA 
decreased by 35% and 52%, respectively, in mice treated with PQ (Chen et al. 2008). A 
loss of about 30% in dopamine levels has been reported in mice after exposure to PQ/MB 
(Thiruchelvam et al. 2000a,b). Future experiments will focus on measuring dopamine and 
its metabolites. 
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4.4 Specificity of PQ-induced Loss of Neurons 
Our results have indicated that PQ administration in rats causes the loss of DA 
neurons in the SNc. However, immunostaining to count serotonergic and cholinergic 
neurons has to performed to ensure specificity of PQ. Studies have shown that PQ enters 
DA neurons via DAT present on these neurons (Ossowska et al. 2005b). However, 
toxicity to other areas of the brain has not been very well documented. For this reason, I 
decided to use a general marker for neurons, namely NeuN, to stain various areas of the 
brain during the five injection PQ regime. NeuN is a neuronal-specific protein (Mullen et 
al. 1992) that is frequently used as a neuronal marker for viable and intact neurons (Xu et 
al. 2002, Hassen et al. 2004). Immunohistochemistry of NeuN shows that the marker is 
visible both in nuclei and in portions of the cytoplasm of neurons, such as the cell body, 
axons and dendrite processes (Mullen et al. 1992). Data from the second phase of study 
clearly revealed that even with a higher dose of PQ, damage was caused specifically to 
the DA neurons in the SNc. Results indicated a decrease in NeuN-immunopositive 
neurons in the SNc following PQ injections, but no difference in NeuN immunostaining 
in other areas of the brain; e.g. hippocampal region and cortex (Figure 3.13 A,B) between 
the saline and PQ groups was observed. McCormack et al. (2002) also reported the 
specificity of PQ-induced DA loss in mice. Their study revealed that PQ does not target 
the hippocampus or the neurons in the substantia nigra pars reticulata (SNr) which are 
anatomically adjacent to the SNc where PQ causes damage. Future experiments will 
examine the neuronal counts in the ventral tagmental area (VTA) as well as the SNr. 
I also stained the brain sections with H&E and pathologists confirmed that no 
gross changes in morphology occurred in the brain of rats treated with PQ (Figure 
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3.13D). Furthermore, the intraperitoneal treatment did not cause any damage to the liver 
or the kidneys (as assessed by pathologists) (Figure 3.15). Damage to lungs due to acute 
dosing of PQ has been shown (Dinis-Oliveira et al. 2006). However, due to technical 
difficulties, the analysis of the lungs could not be performed. 
4.5 The Mechanism of PQ Toxicity 
The mechanism of PQ neurotoxicity appears to be mediated by oxidative stress. 
Superoxide anion radicals are generated through redox cycling reactions of PQ with 
oxygen as well as with NADH-oxidoreductases (Peng et al. 2007) These superoxide 
anion radicals can then lead to the formation of ROS (Figures 1.7, 1.8). The damage 
inflicted by ROS in tissues can be evaluated by measuring the modifications to 
biomolecules such as proteins, DNA and lipids. 
Studies have shown that there is a loss in the GSH during oxidative stress. Again, 
results revealed a reduced content of GSH in the brains of PQ-treated rats, consistent with 
its utilization to combat the effects of PQ (Figures 3.3, 3.9, 3.20). Recent studies have 
pointed out that PQ induces alternation of GSH levels in the SNc in mice. Levels of GSH 
in the SNc have decreased more for the PQ group (10 mg/kg) than for the control group, 
while levels of oxidized glutathione (GSSG) increased in the SNc region (Kang et al. 
2009). 
Lipid peroxidation is another method to monitor the oxidative damage caused by PQ. 
The end products of lipid peroxidation are usually 4-hydroxy nonenal (4-HNE) and 
malondialdehyde (MDA). I also attempted to measure the levels of lipid peroxidation by 
measuring these end products. Immunostaining procedures for 4-HNE have been 
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standardized and will be used to complement the data. I have successfully measured the 
levels of MDA using thiobarbituric acid assay. Our results show increased levels of lipid 
peroxidation in the SNc in PQ treated animals (Figures 3.5, 3.10). Similar results have 
been shown in mice treated with PQ exposure caused an increase in the number of 
midbrain cells positive for 4-hydroxy-2-nonenal, a marker of lipid peroxidation 
(McCormack et al. 2006). Increased lipid peroxidation in the striatum and midbrain 
regions of mice exposed to PQ (Thiruchelvam et al. 2005). Increased lipid peroxidation 
could lead to the changes in the membrane properties and affect cellular homeostasis 
(Dinis-Oliveira et al. 2006). 
Oxidative stress also leads to mitochondrial dysfunction. Production of ROS leads to 
increased formation of superoxide anion radical which can then form peroxynitrite by 
reacting with nitric oxide. This peroxynitrite can impair the mitochondrial respiratory 
chain and lead to decreased ATP synthesis (Ebadi and Sharma 2003). Consistent with 
these phenomena, I also found reduced ATP levels in rat brains following PQ exposure 
(Figures 3.6, 3.11). Postmortem degradation of ATP is known to occur during tissue 
extraction (Delaney and Geiger 1996). Since, the experimental conditions were the same 
for all the rats dissected, the postmortem degradation of ATP is relatively the same for all 
animals. Moreover, I have measured the relative levels of ATP and compared the results 
between different groups. The solution to this issue is using a high-energy focused 
microwave irradiation method, which involves rapid inactivation of enzymes and allows 
for the measurement of endogenous ATP (Delaney and Geiger 1996). Using in vitro 
assays, I have shown that PQ can destabilize the mitochondria from differentiated human 
neuroblastoma cells (McCarthy et al. 2004). Therefore, there is strong evidence 
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suggesting that dysfunctional mitochondria and oxidative stress are most likely the 
significant contributors to the PQ-induced neurotoxicity. 
Systemic exposure of rodents to PQ, alone or in combination with the maneb, 
mimics the pathological features of PD, such as the intra-neuronal deposition of a-
synuclein as well the selective degeneration of DA neurons in the SNc (Manning-Bog et 
al. 2002, McCormack et al. 2002, Peng et al. 2004). In order to evaluate the levels of a-
synuclein in the frontal cortex and midbrain, western blot analysis was performed. 
However, our results did not show any increase in levels of a-synuclein (Figure 3.12). 
Although preliminary, this study needs to be repeated with more animals. Similarly no 
increase in the levels of Parkin was observed in our study (Figure 3.12). 
I also tried to estimate the levels of iNOS but was not successful. Once activated, 
iNOS produces nitric oxide which can react with superoxide anion radical to form 
peroxynitrite. One potential target of peroxynitrite is tyrosine hydroxylase (TH). 
Inactivation by nitration of TH by peroxynitrite appears to be a key process in the 
development of PD in humans (Symeyne and Jackson-Lewis 2005). 
Dopamine is also subjected to free radical attack especially by hydroxyl radical 
and autooxidation in the extracellular space. Moreover, dopamine can also be nitrated 
intracellularly and therefore may cause degeneration of neurons containing this 
neurotransmitter (Symeyne and Jackson-Lewis 2005). 
Oxidative stress, c-Jun N-terminal kinase activation, and a -synuclein aggregation 
are each induced by PQ, but details of the cell death mechanisms involved remain 
unclear. Recently, a Bak-dependent cell death mechanism for PQ-induced neurotoxicity 
has been reported. PQ-induced biochemical features that were consistent with apoptosis, 
126 
included cytochrome c release, with subsequent caspase-3 and poly (ADP-ribose) 
polymerase cleavage (Fei et al. 2008). 
In order to make a model of neurodegeneration functionally relevant, a 
behavioural component is necessary. Consideration of PQ as a candidate neurotoxicant 
requires that systemic delivery not only produces DA neuron loss in the SNc, but also 
exhibits the resultant neurobehavioral syndrome reflecting depletion of dopamine 
terminals within the striatum. Decreased motor activity has been reported following PQ 
exposure in mice (Brooks et al. 1999). Stepping impairments can be assessed using a 
rotorod. Stepping impairments are assessed by counting the number of adjusting steps 
taken by a rat while moving on a rotating rod. While the animals move on the rotorod, 
they are videorecorded from the front, lateral and posterior views. The recorded 
behaviour is then analysed frame by frame (Whishaw et al. 2003). I was interested in 
evaluating the translational effects of loss in DA neurons to change in behaviour. In the 
first phase of our study, PQ affected rats showed clear signs of deficiency in fine motor 
control as indicated by a reduced tendency to turn around and walk backwards on the 
rotorod (Figure 3.7). The data for the second phase is currently being analysed. 
4.6 Neuroprotective Effects of WS-CoQio 
Our results indicate that PQ causes a loss in DA neurons in the SNc, induces 
oxidative stress, mitochondrial dysfunction as well as behavioural deficits. Furthermore, I 
have established that the brain damage and the performance deficits could be minimized 
by giving the animals WS-CoQio, which contained WS-CoQio and derivatised vitamin E 
and was provided throughout the duration of the experiment. I eliminated the 
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neurotoxicity of PQ by providing the animals with drinking water containing WS-C0Q10, 
administered three weeks prior to PQ exposure and throughout the duration of the 
experiment. Data have also shown that placebo does offer some protection against 
oxidative stress; however placebo alone is not sufficient to protect the neurons from 
undergoing neuronal death induced by PQ. The placebo formulation consists of vitamin-
E and poly ethylene glycol. Coenzyme Qio (C0Q10) on the other hand, works at the 
mitochondrial level and does prevent neuronal cell death induced by PQ. The preliminary 
studies using WS-C0Q10 as a therapeutic agent also showed the ability of this compound 
to offer protection after inducing damage to the nigral cells with PQ. Despite statistical 
lack of significance due to a small group of rats used in this study, this formulation has 
shown that it can protect the rats against PQ toxicity. 
My data adds to the mounting evidence that antioxidants, especially C0Q10 and 
vitamin E, are important for the management of neurodegenerative diseases (McDonald 
et al. 2005). Vitamin E has been tested for its potential as a neuroprotectant, however, it 
proved to be a failure (Beal 2001). Neuroprotective effects of C0Q10 in the CNS has been 
extensively evaluated (Beal and Matthews, 1997, Cleren et al. 2008) and numerous in 
vivo studies demonstrate its protective role against experimental ischemia, sparing the 
levels of GSH and ATP (Beal 2003, Sikorska et al. 2003). CoQio is a highly 
hydrophobic, naturally occurring compound that primarily functions in mitochondrial 
membranes as a diffusible electron carrier of the mitochondrial respiratory chain 
complexes. It is also a powerful antioxidant readily scavenging for free radicals (Beal 
2003). Its pharmaceutical applications, however, seem to suffer from the lack of 
solubility and low bioavailability, both which are needed to achieve therapeutic effect. 
An open-label phase I clinical trial of CoQio in PD patients reveal good absorption and 
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tolerance of C0Q10, however, very high dosages were required (up to 1200 mg per day) to 
achieve some beneficial effects. Although very encouraging results were acquired from 
this study, the authors express a concern that PD patients would have to take such a high 
dosage of C0Q10- (Shults et al. 2002, Shults et al. 2004). 
A recent study has shown that oil soluble Tishcon CoQio formula provided significant 
protection against MPTP toxicity in a mouse model (Cleren et al. 2008). However the 
effective doses used in this work were 200 mg/kg/day -1600 mg/kg/day (equivalent to 14 
g/day-114 g/day for a 70 kg patient). This dose is extremely high and unlikely to be used 
in human patients. On the other hand the effective daily dose of water soluble formulation 
used in my study that offered significant neuroprotection is 5 mg/kg/day in rats, roughly 
one fourth of the dose used in the aforementioned clinical trial and 40 times less than the 
dose used by (Cleren et al. 2008) in mice. The more recently developed water soluble 
formulation of CoQio (WS-CoQio) has been reported to be more effective as it combines 
two potent antioxidants, i.e., derivatised vitamin E (PTS) and CoQio (Sikorska et al. 
2003, Borowy-Borowski et al. 2004, www.Zymes.com). PTS is a pro-drug form of 
vitamin E (a-tocopherol), which was chemically derivatised by sebacic acid and 
polyethyleneglycol (PEG) and used a component (carrier) in WS-CoQio formulation 
(Sikorska et al. 2003). These two compounds form a stable and water soluble complex 
thereby causing them to be easy to deliver and test (i.e., in drinking water). The effective 
daily dose of this formulation that offered significant neuroprotection in our study will 
translate to 350 mg/day for a 70 kg human subject (roughly one fourth of the dose used in 
the aforementioned clinical trial). Furthermore, rats fed with the WS-CoQio containing 
diet have shown elevated plasma levels of CoQio (Sikorska et al. 2003). Due to the 
water-soluble nature of our formulation, I have done extensive work on its effect as 
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neuroprotective agent in neuronal cell cultures (Sandhu et al. 2003, McCarthy et al. 2004, 
Somayajulu et al. 2005). In my previous in vitro studies I have shown that this 
formulation of CoQio protects differentiated SHSY-5Y cells against PQ toxicity by 
stabilizing mitochondrial membranes, maintaining mitochondrial membrane potential and 
sustaining ATP production (McCarthy et al. 2004). More recently, I established that it 
inhibits Bax activity and prevents Bax-induced destabilization of mitochondria in 
mammalian cells (Naderi et al. 2006). Thus this formulation has advantages over the 
current formulations being used. 
4.7 Elucidating the Probable Mechanism of Neuroprotection by WS-CoQio. 
Studies using PQ have shown that WS-CoQio can offer neuroprotection in vivo. 
This formulation decreased the numbers of DA neurons undergoing cell death as well as 
protected against PQ-induced oxidative stress and subsequent mitochondrial dysfunction. 
In vitro studies have shown that WS-CoQio can offer neuroprotection against glutamate 
toxicity, PQ toxicity and also hydrogen peroxide induced toxicity (Sandhu et al. 2003, 
McCarthy et al. 2004, Somayajulu et al. 2005). 
This raises the question: Is the neuroprotective ability of WS-CoQio solely based 
on the fact that it is acts as an anti-oxidant? However, this is not the case. It has been 
observed that when only the reduced formulation of CoQio is used as a neuroprotective 
agent, it is toxic to the cells and could not protect them against oxidative stress (Sikorska 
et al. personal communication). Interestingly, results using equimolar concentrations of 
reduced and oxidized forms of CoQio offered neuroprotection against oxidative stress and 
other apoptotic inducing agents. Vitamin-E and polyethylene glycol are used as carriers 
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to solubilize C0Q10 and help in the uptake of this compound by the cells. Studies aimed at 
evaluating the bioavailability of this formulation established that cells were capable of 
internalizing WS-C0Q10 when it was added to the media as an aqueous solution (Borowy-
Borowski et al. 2004). A 3-day exposure tolO jug/ml of WS-C0Q10, caused an increase in 
cellular mitochondrial membranes from 13.3 ng/106 cells to 27.5 ng/106 cells and an 
increase in membranes from 0.7 to 6.0 ng/106 cells. The treatment also caused an increase 
in total cellular levels of ATP as compared to untreated cells (Sandhu et al. 2003). This 
formulation also further resulted in the prevention of mitochondrial collapse under 
oxidative stress induced by PQ in vitro (McCarthy et al. 2004). These studies have 
indicated that this formulation does enter the mitochondrial membrane and stabilize the 
mitochondrial membrane by increasing the efficiency of the electron transport chain 
(ETC). If the electrons are transferred efficiently via ETC, then the conversion of oxygen 
to superoxide anion radical can be prevented. Our studies using isolated mitochondria 
have shown that WS-CoQio can offer neuroprotection against rotenone and PQ-induced 
toxicity (Figure 3.21). 
More interestingly, in vitro studies have indicated that WS-CoQio can prevent 
cells from Bax-induced mitochondrial damage (Figure 3.22) (Naderi et al. 2006). Recent 
studies have reported the involvement of Bak in mediating the toxicity of PQ (Fei et al. 
2008). Bax belongs to the family of pro-apoptotic factors which also include Bad, Bax, 
Bid, Bak and Bim amongst others and can permeabilize the outer mitochondrial 
membrane or bind to the voltage dependent anionic channel (VDAC) and cause the 
opening of this channel. VDAC is a component of the mitochondrial permeability 
transition pore (PTP). Bax binding therefore can lead to the leakage of cytochrome c, and 
other factors from the mitochondria to the cytosol, which can induce apoptosis (Naderi et 
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al. 2006). Two mechanisms of neuroprotection by WS-C0Q10 are possible in this 
scenario: (1) WS-C0Q10 can associate with Bax and prevent its binding to mitochondria 
and (2) WS-CoQio can bind to the VDAC and prevent the binding of Bax to the channel. 
Previous studies have shown that there are ubiquinone binding sites on the PTP. 
Furthermore, binding of ubiquinone to PTP can inhibit the opening of the pore (Fontaine 
etal. 1998). 
Results from my study indicate that PQ as well as PQ-WS-CoQio may cause the 
activation of astroglia, a feature of neuroinflammation. Therefore it is speculated that 
WS-CoQio can cause astrocyte activation, which could be that be neuroprotective. 
However, I do not have sufficient data for extrapolation currently. 
4.8 Role of Astroglial Activation in Neuronal Cell Death and Neuroprotection 
There appears to be a great amount of communication between neurons and non 
neuronal milieu. Astrocytes are the most abundant cell type in the CNS and provide an 
essential metabolic support to neurons, including regulation of ion homeostasis, GSH 
metabolism, free radical scavenging and regulation of the blood-brain barrier. GSH acts 
as an important intracellular antioxidant due to its ability to detoxify lipid and organic 
peroxides including peroxynitrite. Activation of glial cells in the CNS in response to 
injuries or neuropathological processes is well known and documented phenomenon, 
although not always linked to neuroprotection (Eddleston and Mucke 1993, Drukarch et 
al. 1998, Hailer et al. 2001, Liberto et al. 2004, Hanisch 2007) Although preliminary, I 
have observed in this study, the activation of astrocytes in all the PQ-treated groups after 
GFAP-immunostaining (Figure 3.17) as well as an increased expression of this protein in 
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western blot analysis (Figure 3.12). Results from my study are intriguing because 
astrocyte activation was also increased in PQ-WS-C0Q10 treated animals. Surprisingly, 
the levels of activated astrocytes were not reduced in the presence of WS-CoQio- This 
suggests that WS-CoQio may cause the release of neuroprotective cytokines and this is 
novel (Figure 31). I observed an increase in the expression of the cytokine L-Selectin or 
CD26L/LECAM-1. Further studies are needed to completely understand the 
neuroprotective role of inflammation in PD, while using WS-CoQio as a neuroprotectant. 
Activated astrocytes produce neurotrophic factors (i.e., Nerve growth factor 
(NGF), Glial cell derived neurotrophic factor (GDNF), brain derived neurotrophic factor 
(BDNF), cytokine ciliary neurotrophic factor or CNTF), scavenge excess of neurotoxic 
glutamate and may provide energy substrates for neurons and perform the 
neuroprotective function. For example, astrocytes store and subsequently metabolize 
glycogen to sustain their own energy requirements. They can also export glucose and/or 
lactate to support energy demands of neighbouring neurons (Dringen et al. 1993, 
Brucklacher et al. 2002). My data is consistent with this scenario as the brain steady-state 
ATP content remained unchanged in PQ-treated rats under the neuroprotective 
conditions. In addition, astrocytes are equipped with a robust antioxidant system and 
play a major role in GSH metabolism and neuroprotection (Peuchen et al. 1997, Wilson 
1997, Dringen et al. 2000, Drigen and Hirrlinger 2003). PQ exposure causes a time-
dependent increase in the number of cells with immunohistochemical and morphological 
features of activated microglia (Purisai et al. 2007). Multiple treatments with PQ or PQ 
and maneb have been associated with activation of microglia, although the relationship 
between this effect and neurodegeneration has yet to be demonstrated (McCormack et al. 
2002, Saint-Pierre et al. 2006). 
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4.9 Conclusions 
In this study, I have successfully induced neuronal loss specific to the SNc in 
Long Evan's hooded rats by 10 mg/kg PQ treatment. Results have revealed that PQ 
induces oxidative stress, mitochondrial dysfunction, astrocyte activation as well as 
reduced motor function. More significantly, I have observed that WS-C0Q10 offers 
protection against PQ-mediated toxicity by not only preventing neuronal loss but also, 
offering defense against oxidative stress, mitochondrial dysfunction and improves motor 
function both as a prophylactic and therapeutic agent. Furthermore, in vitro studies 
revealed protection against mitochondrial damage induced by rotenone, PQ and Bax. PD 
is diagnosed usually after a substantial loss of DA neurons has occurred. The aim of this 
study is to protect the remaining neurons from undergoing cell death and thus improving 
the quality of life of PD patients. This study is, in fact, the first pre-clinical evaluation of 
WS-C0Q10 as a neuroprotective (prophylactic) agent as well as therapeutic (restorative) 
agent to prevent the loss of DA neurons. 
4.10 Future work 
Majority of the time and effort was spent on standardizing the protocols for 
immunohistochemistry, behavioural studies and the biochemical studies. Results obtained 
from the second phase of the study were performed using fewer numbers of rats. These 
preliminary studies need to be repeated in order to obtain statistically significant data. 
Also, using a larger sample of rats will be beneficial to minimize the issue of variability 
in how the rats respond to PQ treatment. 
134 
This work has significance for finding neuroprotective strategies to arrest the 
progressive loss of DA neurons in PD. Interestingly, under all circumstances; I have 
observed the neuroprotective ability of WS-CoQio- I have initiated the experiments to 
evaluate the role of this formulation as a therapeutic agent. Therapy for PD begins after 
diagnosis, by which time a large number of DA neurons have already been lost. For a 
candidate to be considered as a good therapeutic/ restorative agent, it should be able to 
arrest the further loss of neurons and thereby prevent the progression of this disease. 
Further experiments will be needed to confirm our studies aimed at evaluating the 
potential effects of WS-CoQio as a therapeutic intervention in PD (post-injection 
feeding). Also, the experiments analyzing the effects of age on neuronal loss as well as 
neuroprotection by WS-CoQio need to be thoroughly investigated. Many of the 
biochemical and immunohistochemical assays need to be repeated due to small sample 
size used in the current experiments. 
Bioavailablity of WS-CoQio is very important because it is essential to know 
how much of WS-CoQio can cross the blood brain barrier. Therefore the bioavailability 
of WS-CoQio in the brain tissue as well as the mitochondria in neuronal cells will be 
evaluated. The next set of experiments will include determining levels of WS-CoQio in 
the brain and neuronal mitochondria by HPLC. Toxicopathology of WS-CoQio needs to 
be performed to determine if it is safe for human consumption as this compound is a 
potential candidate for clinical trials. 
Of equal importance is to determine the levels of striatal dopamine and its 
metabolites in PQ treated rats because one of the neurochemical features of PD is the loss 
of dopamine in the striatum. HPLC will be used to determine the levels of striatal 
dopamine and its metabolites. 
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Further studies need to be performed to reveal the role of neuroinflammation in 
development of this disease. Preliminary studies have revealed astrocyte activation in 
PQ-WS-CoQio treated groups. There is a significant implication, and to analyze under 
what circumstances inflammation is protective or toxic is very important. 
Behavioural data for the second phase of the study is currently being compiled. 
Furthermore, new tests are being standardised to assess behavioural impairment. Several 
clinical studies have reported that exercise and balance training in the early stages of PD 
improves overall muscle strength, balance, motor performance, and ambulation in 
patients (Miyai et al. 2000, Bergen et al. 2002, Hassen et al. 2004). A recent study on 
mouse model of PD has shown that endurance exercise training effectively reversed PD-
like behavioral deficits related to regular movement and balance (Konstantinos et al. 
2009). Therefore, studies will be aimed at testing if endurance exercise training might 
enhance the effectiveness of WS-CoQIO treatment. 
Finally, the mechanism of protection of WS-CoQio needs to be elucidated. 
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Contributions to this project 
Honours' Students 2004 - present: 
2004-2005 
Jennifer Vergel de Dios helped with biochemical analysis for phase one studies. 
2006-2007 
Spencer Hills helped standardizing protocols for histochemistry, involved in sectioning 
as well as staining. 
2007-2008 
Anca Matei performed the biochemical analysis for one batch of the 5 injection 
(therapeutic and prophylactic effects of WS-CoQio) regime. 
Edward Schwartzenberger helped with injections, dissections and performed the 
immunohistochemistry for 8 injection regime, standardized (DAB), 4-HNE, alpha-
synuclein, and GFAP staining. He also performed TH immuno-staining for 5 injection 
regime (therapeutic and prophylactic effects of WS-CoQio). He worked with us for 2 
years and so has helped immensely with homogenizing tissues, dissections, and 
performing Bradford assays. 
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2008-2009 
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and also performed GFAP and NeuN immuno-staining, as well as H&E staining for the 
different tissues in the 5 injection regime. Performed all the western blots for Anca's 
thesis in 2007-8 when she was a volunteer. 
Other students involved: 
1. Carly Griffin: Graduate student (cancer project). Helped with dissections. 
2. Sudipa June Chatteijee: Graduate Student (cancer project). Helped with 
dissections and flash freezing tissues for 5 injection animals. 
3. Natasha Rafo: 4th year Honour's student for the year 2009-2010. Has helped with 
injections, dissections, perfusions as well as flash freezing tissues for the 5 
injection animals. 
4. Parvati Dadwal: Volunteer 2008-current. Undergoing training for injections, 
dissections, perfusions, flash freezing tissues. Actively involved in processing 
tissues for histochemistry, sectioned brain tissues for a couple of animals from the 
5 injection animals (old vs. young study and the current tissue processing expert). 
Performed several Bradford assays and helped with the GSH Assays and standard 
curves for the lipid peroxidation assay. 
5. Joe Barkho: Holds the animals during injections. 
6. Cynthia Tran: Helped with dissections for the 5 injection animals. Performed 
Bradford assays for many experiments. 
7. Dennis Ma: Helped in homogenizing tissues for phase 2 experiments. 
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8. Justin Kale: Cast the 10% gels for the western blots and helped with using the 
Photoshop software to layer images. 
9. Pamela Ovadje: Helped with the chemdraw software to draw structures for my 
thesis. 
10. Ren Xiang: Former graduate student from Dr. Zielinski's lab. Trained me to 
perform the perfusions, dissections and separating the different brain parts. 
11.Varakini Parameswaran: Worked for Dr. Cohen and helped with identifying 
animals for injection and dissection periods during phase one studies. 
Other people involved: 
1. Dr. Cohen: Collaborator, studies the behaviuoral component of this 
project. The rotorod data for phase one has been performed by his team. 
2. Dr. Pardeep Jasra: Helped with dissections (2006-2007) and also helped 
with the protocols for cryosectioning. 
3. Dr. T.S. Sridhar: Analyzed all the slides for H&E staining for the brain. 
Valuable suggestions and critique for improvising the biochemical and 
histochemical methodology used in the Pandey lab. 
4. Dr. Jyothi S. Prabhu: Analyzed all the slides for H&E staining for the 
liver, lung, and kidneys. 
164 
5. Ms. Elaine Rupke: Teaching me how to use the CO2 chamber, how to 
draw blood from animals and also injecting animals. 
6. Technicians from the University of Geulph (Department of Pathology): 
Provided me with protocols and tips for paraffin embedding and tissue 
sectioning. 
7. Ms. Patricia Lanthier and Dr. JK Sandhu: NRC Ottawa: Provided me with 





Animals are injected once a week with either saline or lOmg/kg paraquat. 
Injection regimes usually begin a month after the animals arrive and have been handled 
and put on different water regimens. Injections are performed in the Biology building 
(basement: room adjacent to 72). Solutions and supplies are taken to the Biology building 
from Essex Hall. Two people are required for injections: one for holding the animal 
(properly and firmly), and the other for injecting the animal. Mr. Jouseph Barkho is 
currently the person who holds the animals during injections. Efforts are made to ensure 
that animals experience minimal discomfort, pain and distress during the injection 
process. Ms. Elaine Rupke can train/ show a person how to inject intraperitonially in the 
proper way without causing pain or stress to the animals. Following are the steps taken to 
make the process convenient. 
1. Make up a schedule and choose a preferable day and time for injections. 
2. Make 10 mg/ml paraquat in phosphate buffered saline (PBS) pH= 7.6 (recipe in 
materials and methods) and carry 5 ml of PBS pH=7.6. Make sure to label tubes 
correctly. 
3. Weigh the animals and record weights. 
c/o 
4. Use a syringe with a 25G needle and draw up the required volume. 
5. Ensure that there are no air bubbles. 
6. Place the animal in the position favourable for injection. Joe always flips the 
animals upside down and holds the base of the chin and the hind legs. 
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7. Inject the animal on the right side (in the area lower than the rib cage and above 
the hind leg). Inject saline animals first. 
NOTE: PQ is a very toxic chemical and needs to be handled with extreme 
caution. Wear a labcoat. facemask and gloves while using PO and discard the 
gloves after use in the biohazard bag. Also, wash your hands thoroughly with 
soap and water. 
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Appendix B 
Perfusion and Dissections 
All dissections are performed in the dissection room in the animal facility (room 72) 
located in the basement of the Biology building. 
Equipment Preparation 
1. Gloves, labcoat and protective eyewear must be worn during this 
procedure. 
2. A uume hood with sufficient room for equipment and working exhaust 
system. 
3. Perfusion rack, isofurane (anaesthetic) and oxygen cylinder (make sure it 
is not empty). 
4. Perfusion kit consisting of: 
• 4 pairs scissors (2 blunt and 2 sharp), 5 sets of forceps: toothed, 
serrated, coverglass forceps bent, smooth jaw forceps, bone cutting 
forceps. 
• Needles (20G1, with short bevel work best for most rats). 
• Perfusion apparatus (2 clean bottles: one labelled tyrodes and other 
formaldehyde, clean tubes and clasps). 
5. Labelled tubes (50 ml), 70% ethanol solution in a spray bottle, 2L 
containers for storing fixative solution as well as Tyrode's solution with 
heparin 
Fixatives: 10% Formaldehyde in 0.1 M PBS solution pH=7.6. 
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Before you start, check the checklist. 
Checklist: 
Things to bring from Essex Hall: 
1. Tyrode's stock solution 
2. Heparin (added) ? 
3. 10% buffered Formaldehyde stock 
4. Labelled Tubes (rat numbers and cage numbers, date, organ type and batch), 
forceps, scissors, isofurane, ethanol, paper towels, biohazard bags (orange 
coloured) 
In the animal facility: 
• Oxygen cylinder, garbage bag for collecting carcasses and the bottles for 
perfusion. 
• Animal care technician informed 
Procedure 
• Fill the two bottles with corresponding liquids, adjust the tubing and the flow rate 
to 30 ml/minute and ensure no air bubbles are present through the tubing. No 
formalin should be present in the tubing when you start. Rinse the tubing with 
Tyrode's. 
• Weigh the rat and place it into the plastic chamber used for anaesthetising 
animals. Turn on the anaesthetic pump and the oxygen cylinder. Anaesthetize the 
rat into a deep surgical plane. As this is a terminal procedure, it is important that 
the rat be very deeply anaesthetized, but the heart must still be beating. This 
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process takes upto 7-8 minutes, after which the rat will stop moving in the 
chamber. 
• Put the rat into the dissecting tray. Quickly, put the nozzle on the rat's nose and 
hold it in place. 
• Two people are required for this step: One person is responsible for dissections 
while the other person assists (holds the nozzle, helps switch liquids, hands 
equipment needed to the person dissecting). 
• Check to make sure the rat is deeply anaesthetized (usually by pinching one of the 
hind legs with a pair of forceps). If the animal retracts its foot, then put it back in 
the chamber for an additional 5-7 minutes. 
• Spray animal with 70 % ethanol so that the fur doesn't stick to the insides after 
cutting and it is easy to clean fur from the scissors and forceps. 
• Make vertical surgical cut along the chest midline to below the rib cage by pulling 
up flesh with a pair of toothed forceps and cutting with blunt scissors. 
• Using a pair of toothed forceps pinch the sternum and pull up (white cartilage 
flap) and cut through the diaphragm. 
The rest of this procedure must be done quickly to make sure the heart continues to 
pump the blood. 
• Whilst holding the sternum with toothed forceps the in one hand, make lateral 
cuts bisecting ribs on both sides of animal towards armpits. 
• Pull up the rib cage exposing the liver, stomach and heart. 
• Introduce the needle into the left ventricle (on your right as you look down), 
making sure not to pierce through to the left atrium all the way into the aorta. This 
will be the entrance site for the saline and formaldehyde. 
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• Start pumping the Tyrode's solution and make a small cut on the lobe of the liver 
to allow the blood, saline and the formaldehyde to leave the body during 
perfusion. 
• The liver should become pale as the blood drains. Within 30 seconds there should 
be some muscle twitching. Be careful to keep the needle in place all while this 
occurs. The person assisting can hold the tail and the legs to help keep the animal 
in place. 
• Turn of the isofurane and remove the nozzle from the nose at this point. 
• Allow blood to drain; the liquid as it is pumped through will change from dark red 
to clear if the procedure is done properly. 
• Switch the solutions and run the fixative through the animal. Once the front paws 
are stiff (150-200ml of fixative), then turn off the fixative. Remove needle from 
heart. Pour out any liquid left in the rat's chest cavity. 
• Place the rat in the guillotine and remove head for the brain to be harvested. 
• Fix the brain after surgery. For immunocytochemistry for 24 hours then switch to 
70% ethanol and store in 2-8°C. 
• Clean the apparatus thoroughly with antibacterial reagent and wipe down the 
work area. Turn off the O2 cylinder. Shut down the fiimehood. Place the carcasses 
into the cold room (biology basement, just opposite Ms. Rupke's office). 
Autoclave the biohazard bag in Essex Hall before disposing the waste. 
The different apparatus used in this experiment is shown below. 
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Appendix C 
Rat Tissue Snap Freezing 
All dissections are performed in the dissection room in the animal facility (room 72) 
located in the basement of the biology building. 
Equipment Preparation 
• Gloves, lab coat and protective eyewear should be worn during this procedure 
• A fume hood with sufficient room for equipment and working exhaust system 
• Dry ice, liquid nitrogen and carbon dioxide cylinder (make sure it is not empty) 
• Dissection kit consisting of: 
4 pairs scissors (2 blunt and 2 sharp), 5 sets of forceps: toothed, 
serrated, coverglass forceps bent, large forceps bent, bone cutting 
forceps 
• Guillotine 
• Clean labelled tubes 
Before you start, check the checklist. 
Checklist: 
Things to bring from Essex Hall: 
• Dry ice 
• Liquid Nitrogen 
• Labelled Tubes, forceps, scissors, ethanol, paper towels, bags for collecting 
carcasses and biohazard bags (orange coloured) 
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In the animal facility: 
• Carbon dioxide cylinder, garbage bag for collecting carcasses 
• Animal care technician should be informed about the dissections 
Procedure 
• Weigh the rat and place it into the gas chamber. Turn the nozzle on the CO2 
cylinder so that the gas flows into the chamber. The first rat will take about 5-6 to 
minutes to "fall asleep." (Once the chamber is filled with CO2, the other rats take 
less time) Wait till the rat stops moving in the chamber. Make sure that the rat is 
"asleep" by checking the heart beat and by giving an obnoxious stimulus to the 
hind leg. Make sure that the exhaust tube for the chamber is in the fumehood and 
the fan is on. 
• Put the rat into the guillotine and swiftly decapitate. 
• Two people are required for this step: One person is responsible for dissecting the 
brain and flash freezing tissues while the other person is responsible for dissecting 
the other organs i.e. liver, lungs, heart, spleen and kidneys and passing them onto 
the person responsible for flash freezing. 
• Spray animal with 70 % ethanol so that the fur doesn't stick to the insides after 
cutting and it is easy to clean for from the scissors and forceps. 
• Make vertical surgical cut along the chest midline to below the rib cage by pulling 
up flesh with a pair of toothed forceps and cutting with blunt scissors. 
• Using a pair of toothed forceps pinch the sternum and pull up (white cartilage 
flap) and cut through the diaphragm. 
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Whilst holding the sternum with toothed forceps the in one hand, make lateral 
cuts bisecting ribs on both sides of animal towards armpits. 
Pull up the rib cage exposing the liver, stomach and heart. 
Cut a small piece of the liver, mince it fine with the scalpel and flash freeze (make 
sure that the tissue is frozen and there is no liquid nitrogen in the tube when you 
place the cap on it. Follow these steps inside the fumehood and lower the barrier 
while dealing with liquid nitrogen. These steps require caution) 
Follow the same with the heart, lungs, kidneys and spleen. 
Meanwhile dissect the brain and make a coronal cut just at the base of the optic 
chiasm and remove the cerebellum. This procedure has been followed for the 5 
injection regime (for 3 injection animals, the striatum was separated from the 
substantia nigra region before freezing). 
Freeze each part separately. 
Place the tissues on dry ice. Bring the tissues back to Essex Hall. Place the tubes 
in labelled Ziploc bags and place them in -80°C in Dr. Mutus' lab in the shelf 
allotted to the Pandey lab. 
Clean the apparatus thoroughly with antibacterial reagent and wipe down the 
place. Turn off the CO2 cylinder. Shut down the fumehood. Place the carcasses 
into the cold room (Biology basement, just opposite Ms. Rupke's office). 
Autoclave the biohazard bag in Essex Hall before disposing the waste. 
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The different apparatus used in this experiment is shown below. 




Paraffin Embedding and Sectioning on the Microtome 
Paraffin embedding and sectioning are performed in Essex 282-1. 
Equipment Preparation 
• Wear gloves, labcoat and protective eyewear during this procedure 
• Two 50 ml tubes with melted Paraffin 
• Embedding rings and steel moulds for preparing paraffin blocks 
• Microtome 
• Water bath at 60°C for embedding and 40°C for sectioning 
• Fresh 70%, 80%, 95% and anhydrous ethanol (EtOH) and xylene 
• Blades for microtome 
Procedure 
• Trim the tissue. For the second phase study, we placed a coronal cut at the optic 
chaism and cut the brain into two pieces and saved both the pieces. (Please refer 
to the picture below). For the first phase of the study, a 3-4 mm piece was 
obtained as shown in the picture and processed. 
During phase 1 study During the phase 2 study 
Tissue of interest 178 Tissue of interest 
The tissue of interest was then processed for paraffin embedding. For the 5 
injection study, the tissue is incubated with following solutions: 
1. Fresh 70% EOH for 1 hour 
2. 80% EOH for 1 hour 
3. 95% EOH for 1 hour 
4. Anhydrous EOH for 3 hours 
5. Xylene 1 hour and 15 minutes 
6. Rinsed with melted paraffin and then placed in paraffin overnight in the water 
bath at 60°C 
Tissues were placed in a steel mould, paraffin was poured, and tissue of interest 
was placed in the mould, followed by the embedding ring and finally topped off 
with paraffin. 
The paraffin was allowed to solidify (3-4 hours at room temperature) and the 
mould was turned upside down and gently tapped with a pair of forceps to obtain 
the paraffin embedded tissue (block) was obtained. 
The block was then placed on the microtome, secured and the position was 
adjusted for obtaining sections. 
Initially the microtome is set at about 40 microns and the block is sectioned at this 
thickness till tissue starts appearing in the wax ribbon. 
The tissue is then trimmed at 20 microns and a stereotaxic rat atlas is referred to 
until the region of interest is reached (Figure 70- the substantia nigra pars 
reticulate is seen). 
Once the region of interest is reached, 6 sections are taken at 8 microns. 
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• A ribbon of 6 sections is placed in the water bath at 40°C and allowed to stretch. 
• A slide is used to scoop up 4 sections and then placed in a trough and dried at 
room temperature overnight. 
• Sections are taken across the whole substantia nigra region and put onto slides. 
• The slides are labelled (correctly: cage number, rat number e.g. 1-1, batch slide 
numbers as l,2...n ) and placed in a plastic slide box that holds 100 slides until 
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